




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 217/22, 405/04, 401/06, 409/04, 491/04, A61K 31/47 // (C07D 491/04, 317:00, 221:00)	A1	(11) International Publication Number: WO 99/20608 (43) International Publication Date: 29 April 1999 (29.04.99)
(21) International Application Number: PCT/EP98/06353 (22) International Filing Date: 5 October 1998 (05.10.98) (30) Priority Data: 9721964.6 16 October 1997 (16.10.97) GB (71) Applicant (for GB only): PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). (71) Applicant (for all designated States except GB US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NJ 10017 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BARBER, Christopher, Gordon [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). FISH, Paul, Vincent [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). DICKINSON, Roger, Peter [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).		(74) Agents: HAYLES, James, Richard et al.; Pfizer Limited, European Patent Dept., Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: ISOQUINOLINES AS UROKINASE INHIBITORS <div style="text-align: center;">(I)</div> (57) Abstract <p>Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein one of R¹ and R² is H and the other is N=C(NH₂)₂ or NHC(=NH)NH₂, and the other substituents are as defined herein, are urokinase (uPA) inhibitors.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakistan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ISOQUINOLINES AS UROKINASE INHIBITORS

This invention relates to certain isoquinolines useful as urokinase inhibitors, and in particular to isoquinolinylguanidines useful as urokinase inhibitors.

5

Urokinase (urinary-type plasminogen activator or uPA; International Union of Biochemistry classification number EC.3.4.21.31) is a serine protease produced by a large variety of cell types (smooth muscle cells, fibroblasts, endothelial cells, macrophages and tumour cells). It has been implicated as playing a key role in cellular invasion and tissue remodelling. A principal substrate for uPA is plasminogen which is converted by cell surface-bound uPA to yield the serine protease plasmin. Locally produced high plasmin concentrations mediate cell invasion by breaking down the extracellular matrix. Important processes involving cellular invasion and tissue remodelling include wound repair, bone remodelling, angiogenesis, tumour invasiveness and spread of metastases.

15

Beneficial effects of urokinase inhibitors have been reported using anti-urokinase monoclonal antibodies and certain other known urokinase inhibitors. For instance, anti-urokinase monoclonal antibodies have been reported to block tumour cell invasiveness *in vitro* (W.Hollas, et al, *Cancer Res.* 51:3690; A.Meissauer, et al, *Exp.Cell Res.* 192:453 (1991); tumour metastases and invasion *in vivo* (L.Ossowski, *J.Cell Biol.* 107:2437 (1988)); L.Ossowski, et al, *Cancer Res.* 51:274 (1991)) and angiogenesis *in vivo* (J.A.Jerdan et al, *J.Cell Biol.* 115[3 Pt 2]:402a (1991). Also, AmilorideTM, a known urokinase inhibitor of only moderate potency, has been reported to inhibit tumour metastasis *in vivo* (J.A.Kellen et al, *Anticancer Res.*, 8:1373 (1988)) and angiogenesis / capillary network formation *in vitro* (M.A.Alliegro et al, *J.Cell Biol.* 115[3 Pt 2]:402a).

25

Conditions of particular interest for treatment by urokinase inhibitors include chronic dermal ulcers (including venous ulcers, diabetic ulcers and pressure sores), which are a major cause of morbidity in the ageing population and cause a significant economic burden on healthcare systems. Chronic dermal ulcers are characterised by excessive uncontrolled proteolytic

30

degradation resulting in ulcer extension, loss of functional matrix molecules (e.g. fibronectin) and retardation of epithelisation and ulcer healing. A number of groups have investigated the enzymes responsible for the excessive degradation in the wound environment, and the role of plasminogen activators has been highlighted (M.C. Stacey et al., *Br. J. Surgery*, 80, 596; M. Palolahti et al., *Exp. Dermatol.*, 2, 29, 1993; A.A. Rogers et al., *Wound Repair and Regen.*, 3, 273, 1995). Normal human skin demonstrates low levels of plasminogen activators which are localised to blood vessels and identified as tissue type plasminogen activator (tPA). In marked contrast, chronic ulcers demonstrate high levels of urokinase type plasminogen activator (uPA) localised diffusely throughout the ulcer periphery and the lesion, and readily detectable in wound fluids.


uPA could affect wound healing in several ways. Plasmin, produced by activation of plasminogen, can produce breakdown of extracellular matrix by both indirect (via activation of matrix metalloproteases) and direct means. Plasmin has been shown to degrade several extracellular matrix components, including gelatin, fibronectin, proteoglycan core proteins as well as its major substrate, fibrin. Whilst activation of matrix metalloproteases (MMPs) can be performed by a number of inflammatory cell proteases (e.g. elastase and cathepsin G), the uPA/plasmin cascade has been implicated in the activation of MMPs *in situ*, providing a broad capacity for degrading all components of the extracellular matrix. Furthermore, in addition to its effect on production of plasmin, uPA has been shown to catalyse direct cleavage of fibronectin yielding antiproliferative peptides. Thus, over-expression of uPA in the wound environment has the potential to promote uncontrolled matrix degradation and inhibition of tissue repair. Inhibitors of the enzyme thus have the potential to promote healing of chronic wounds.

Several related enzymes such as tPA, which also acts via production of plasmin, play a key role in the fibrinolytic cascade. Because of this it is important that an inhibitor has adequate potency and selectivity for uPA relative to both tPA and plasmin to avoid the possibility of anti-fibrinolytic side effects.

The utility of such potent and selective urokinase inhibitors is highlighted by the broad range of invasive biological processes mediated by urokinase. These processes include, but are not limited to, wound healing, angiogenesis-dependent conditions such as retinopathy, bone restructuring, embryo implantation in the uterus, infiltration of immune cells into inflammatory sites, ovulation, spermatogenesis, tissue remodelling during wound repair and organ differentiation, fibrosis, local invasion of tumours into adjacent areas, metastatic spread of tumour cells from primary to secondary sites, and tissue destruction in arthritis.

Various aromatic amidines have been reported to inhibit uPA (J.D. Geratz, M.C.-F. Cheng, *Thromb. Diathes. haemorrh. (Stuttg.)*, 33, 230, 1975; J. Stürzebecher, F. Markwardt, *Pharmazie*, 33, 599, 1978; J.D. Geratz et al., *Thromb. Res.*, 24, 73, 1981). The compounds reported in these publications are generally relatively weak and/or non-selective for uPA relative to other related serine proteases. EP 0 568 289 A2 discloses a series of benzo[*b*]thiophene-2-carboxamidines with significantly greater potency and selectivity with respect to tPA and plasmin (see also M.J. Towle et al., *Cancer Res.*, 53, 2553, 1993; A.J. Bridges et al., *Bioorg. Med. Chem.*, 1, 403, 1993).


There are few reports of guanidine derivatives as uPA inhibitors. AmilorideTM (see below) is a weak but selective inhibitor of uPA (J.-D. Vassalli, D. Belin, *FEBS Letters*, 214, 187, 1987), and various substituted phenylguanidines are reported to have a similar level of potency (H. Yang et al., *J. Med. Chem.*, 33, 2956, 1990).



The compounds described herein are potent reversibly-competitive inhibitors of urokinase enzymatic activity, with selectivity for urokinase relative to certain other important proteases, including the fibrinolytic enzymes tissue-type plasminogen activator (tPA) and plasmin.

- 5 The selectivity of the instantly-claimed compounds for inhibition of urokinase over inhibition of other proteases such as tPA and plasmin, and the fact that they inhibit reversibly, prevents them from having thrombogenic properties.

Thus, according to the present invention, there is provided an isoquinolinyguanidine
10 derivative of formula (I) :-



or a pharmaceutically acceptable salt thereof, wherein

- 15 one of R^1 and R^2 is H and the other is $N=C(NH_2)_2$ or $NHC(=NH)NH_2$,

R^3 is H, halogen, C_{1-6} alkyl optionally substituted by one or more halogen, or C_{1-6} alkoxy optionally substituted by one or more halogen,

- 20 R^4 , R^5 , R^6 and R^7 are each independently H, OH, halogen, C_{1-6} alkyl optionally substituted by one or more substituents independently selected from halogen or OH, C_{1-6} alkoxy optionally substituted by one or more halogen, CN, $CO(C_{1-6}$ alkyl optionally substituted by one or more halogen), $(C_m - \text{alkylene})CO_2R^8$, $(C_n - \text{alkylene})CN$, $O(C_n - \text{alkylene})CN$, $O(C_n -$
25 $\text{alkylene})CO_2R^8$, $(C_m - \text{alkylene})CONR^9R^{10}$, $(C_m - \text{alkylene})NR^9COR^{10}$, $O(C_n - \text{alkylene})CONR^9R^{10}$, $(C_m - \text{alkylene})NR^9SO_2R^{11}$, $(C_m - \text{alkylene})S(O)_pR^{11}$, $(C_m -$

alkylene)SO₂NR⁹R¹⁰, CH=CHCOR⁸, CH=CHCONR⁹R¹⁰, CH=CHSO₂R⁸,

CH=CHSO₂NR⁹R¹⁰, CH=CHSO₂aryl, or

a group of formula X-aryl or X-het,

or, where two of R⁴, R⁵, R⁶ and R⁷ are attached to adjacent carbon atoms, they can be taken

5 together to form an -O(C_n - alkylene)O- moiety,

R⁸ is H, C₁₋₆ alkyl optionally substituted by one or more halogen, or aryl(C₁₋₆ alkylene),

R⁹ and R¹⁰ are each independently H, C₁₋₆ alkyl optionally substituted by one or more

10 halogen, aryl(C₁₋₆ alkylene), aryl, heteroaryl or heteroaryl(C₁₋₆ alkylene),

or R⁹ and R¹⁰ may be linked together by an alkylene moiety to form, with the atoms to which they are attached, a 4- to 7-membered ring optionally incorporating an additional hetero-group selected from an O or S atom or a NR¹² group,

15 R¹¹ is aryl, heteroaryl, or C₁₋₆ alkyl optionally substituted by one or more halogen,

R¹² is H, C₁₋₆ alkyl optionally substituted by one or more halogen, or CO(C₁₋₆ alkyl optionally substituted by one or more halogen),

20 X is a direct link, C_n - alkylene, O, (C_n - alkylene)O, O(C_n - alkylene), CH(OH), C(C₁₋₆ alkyl)OH, CO, S(O)_p(C_m - alkylene), (C_m - alkylene)S(O)_p, CH=CH, or C≡C,

“aryl” is phenyl or naphthyl optionally substituted by one or more substituents independently selected from halogen, C₁₋₆ alkyl optionally substituted by one or more substituents

25 independently selected from halogen and OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, CO(C₁₋₆ alkyl optionally substituted by one or more halogen), (C_m - alkylene)CO₂R¹³, O(C_n - alkylene)CO₂R¹³, (C_m - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴COR¹⁵, O(C_n - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)S(O)_pR¹³, (C_m - alkylene)SO₂NR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴SO₂R¹⁶, CH=CHSO₂R¹³,
30 CH=CHSO₂NR¹⁴R¹⁵, CH=CHSO₂aryl¹, CH=CHCOR¹³, and CH=CHCONR¹⁴R¹⁵,

“heteroaryl” is an optionally benzo-fused 5- or 6-membered heterocyclic group linked by any available atom in the heterocyclic or benzo-ring (if present), which heterocyclic group is selected from dioxolyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl and pyranlyl,

said “heteroaryl” group being optionally substituted by one or more substituents independently selected from halogen, C₁₋₆ alkyl optionally substituted by one or more substituents independently selected from halogen or OH, C₁₋₆ alkoxy optionally substituted

by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, CO(C₁₋₆ alkyl optionally substituted by one or more halogen), (C_m - alkylene)CO₂R¹³, O(C_n - alkylene)CO₂R¹³, (C_m - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴COR¹⁵, O(C_n - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴SO₂R¹⁶, (C_m - alkylene)S(O)_pR¹³, (C_m - alkylene)SO₂NR¹⁴R¹⁵, CH=CHCOR¹³, CH=CHCONR¹⁴R¹⁵, CH=CHSO₂R¹³,

CH=CHSO₂NR¹⁴R¹⁵, or CH=CHSO₂aryl¹,

“het” is an optionally benzo-fused 5- or 6-membered heterocyclic group linked to the “X” moiety by any available atom in the heterocyclic or benzo-ring (if present), which heterocyclic group is selected from dioxolyl, dioxolanyl, furyl, thienyl, pyrrolyl, oxazolyl, oxazinyl, thiazinyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl and pyranlyl, or a fully unsaturated, partially or fully saturated analogue thereof,

such “het” group being optionally substituted by one or more substituents independently selected from halogen, C₁₋₆ alkyl optionally substituted by one or more substituents

independently selected from halogen and OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, CO(C₁₋₆ alkyl optionally substituted by one or more halogen), (C_m - alkylene)CO₂R¹³, O(C_n - alkylene)CO₂R¹³, (C_m - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴COR¹⁵, O(C_n - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴SO₂R¹⁶, (C_m - alkylene)S(O)_pR¹³, (C_m - alkylene)SO₂NR¹⁴R¹⁵, CH=CHCOR¹³, CH=CHCONR¹⁴R¹⁵, CH=CHSO₂R¹³, CH=CHSO₂NR¹⁴R¹⁵, and CH=CHSO₂aryl¹,

“aryl¹” is phenyl or naphthyl optionally substituted by one or more substituents independently selected from halogen, C₁₋₆ alkyl optionally substituted by one or more substituents independently selected from halogen or OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, CO(C₁₋₆ alkyl optionally substituted by one or more halogen), (C_m - alkylene)CO₂R¹³, O(C_n - alkylene)CO₂R¹³, (C_m - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴COR¹⁵, O(C_n - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)S(O)_pR¹³, (C_m - alkylene)SO₂NR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴SO₂R¹⁶, CH=CHSO₂R¹³, CH=CHSO₂NR¹⁴R¹⁵, CH=CHCOR¹³, and CH=CHCONR¹⁴R¹⁵,

R¹³ is H, C₁₋₆ alkyl optionally substituted by one or more halogen, or aryl²(C₁₋₆ alkylene),

R¹⁴ and R¹⁵ are each independently H, C₁₋₆ alkyl optionally substituted by one or more halogen, aryl²(C₁₋₆ alkylene), aryl², heteroaryl¹ or heteroaryl¹(C₁₋₆ alkylene),

or R⁹ and R¹⁰ may be linked together by an alkylene moiety to form, with the atoms to which they are attached, a 4- to 7-membered ring optionally incorporating an additional hetero-group selected from an O or S atom or a NR¹² group,

R¹⁶ is aryl², heteroaryl¹, or C₁₋₆ alkyl optionally substituted by one or more halogen,

“aryl²” is phenyl or naphthyl optionally substituted by one or more substituents independently selected from halogen, C₁₋₆ alkyl optionally substituted by one or more substituents independently selected from halogen or OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, or CO(C₁₋₆ alkyl optionally substituted by one or more halogen),

“heteroaryl¹” is an optionally benzo-fused 5- or 6-membered heterocyclic group linked by any available atom in the heterocyclic or benzo-ring (if present), which heterocyclic group is selected from dioxolyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl,

imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl and pyranyl,

said "heteroaryl" group being optionally substituted by one or more substituents

independently selected from halogen, C₁₋₆ alkyl optionally substituted by one or more

5 substituents independently selected from halogen or OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, or CO(C₁₋₆ alkyl optionally substituted by one or more halogen),

wherein the "C-alkylene" linking groups in the definitions above are linear or branched, and

10 are optionally substituted by one or more (C₁₋₆ alkyl optionally substituted by one or more halogen) groups,

m is an integer from 0 to 3,

15 n is an integer from 1 to 3,

and

p is an integer from 0 to 2.

20

Pharmaceutically-acceptable salts are well known to those skilled in the art, and for example include those mentioned by Berge et al, in J.Pharm.Sci., 66, 1-19 (1977). Suitable acid addition salts are formed from acids which form non-toxic salts and include the hydrochloride, hydrobromide, hydroiodide, nitrate, sulphate, bisulphate, phosphate, 25 hydrogenphosphate, acetate, trifluoroacetate, gluconate, lactate, salicylate, citrate, tartrate, ascorbate, succinate, maleate, fumarate, gluconate, formate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate and p-toluenesulphonate salts.

When one or more of the substituents on the compound of formula (I) contains an acidic

30 moiety, suitable pharmaceutically acceptable base addition salts can be formed from bases

which form non-toxic salts and include the aluminium, calcium, lithium, magnesium, potassium, sodium, zinc, and pharmaceutically-active amines such as diethanolamine, salts.

Alkyl groups, including the alkyl moiety of alkoxy groups, may be straight-chain, branched-
5 chain or cyclic where the number of carbon atoms allows.

“Halo” refers to fluoro, chloro, bromo and iodo.

Certain of the compounds of the formula (I) may exist as geometric isomers. Certain of the
10 compounds of the formula (I) may exist as tautomers. The compounds of the formula (I) may possess one or more asymmetric centres and so exist in two or more stereoisomeric forms. The present invention includes all the individual tautomers, stereoisomers and geometric isomers of the compounds of formula (I) and mixtures thereof.

15 Preferably, R^1 is $N=C(NH_2)_2$ or $NHC(=NH)NH_2$ and R^2 is H.

Preferably, at least two of R^4 , R^5 , R^6 and R^7 are H.

Preferably, R^3 is H, halogen or C_{1-6} alkyl optionally substituted by one or more halogen.

20 More preferably, R^3 is H, Cl, Br or methyl optionally substituted by one or more halogen. Most preferably, R^3 is H, Cl, Br or methyl.

Preferably, R^4 is H, OH, halogen, C_{1-6} alkyl optionally substituted by one or more substituents independently selected from halogen or OH, C_{1-6} alkoxy optionally substituted
25 by one or more halogen, CN, $(C_m - \text{alkylene})CONR^9R^{10}$, $O(C_n - \text{alkylene})CONR^9R^{10}$, $(C_m - \text{alkylene})SO_2NR^9R^{10}$, or a group of formula X-aryl or X-het.

More preferably, R^4 is H, Br, OH, CN, C_{1-6} alkoxy, C_{1-6} alkyl optionally substituted by one or more OH, $SO_2NR^9R^{10}$, $CONR^9R^{10}$, $OCH_2CONR^9R^{10}$, $OCH_2\text{aryl}$, het or aryl.

Yet more preferably, R^4 is H, Br, OH, CN, C_{1-6} alkoxy, C_{1-6} alkyl optionally substituted by one or more OH, $SO_2NR^9R^{10}$, $CONH(aryl(C_{1-6} alkyl))$, $CONH_2$, $OCH_2CONR^9R^{10}$, OCH_2aryl , phenyl or naphthyl.

Most preferably, R^4 is H, Br, CN, OCH_3 , SO_2NH_2 , CH_2OH , $CONH_2$, OCH_2CONH_2 ,

5 $CONHBn$, OBn , OH or Ph.

Preferably, R^5 is H, halogen, or C_{1-6} alkyl optionally substituted by one or more substituents independently selected from halogen or OH.

More preferably, R^5 is H, Br or methyl optionally substituted by one or more halogen.

10 Most preferably, R^5 is H, Br or methyl.

Preferably, R^6 is H, halogen, C_{1-6} alkyl optionally substituted by one or more substituents independently selected from halogen or OH, C_{1-6} alkoxy optionally substituted by one or more halogen, CN, $O(C_n - alkylene)CN$, $(C_n - alkylene)CN$, $(C_m - alkylene)CONR^9R^{10}$, $(C_m - alkylene)CO_2R^8$, $(C_m - alkylene)SO_2NR^9R^{10}$, $(C_m - alkylene)S(O)_pR^{11}$ or a group of formula X-aryl or X-het.

15 More preferably, R^6 is H, Cl, Br, C_{1-6} alkyl optionally substituted by one or more OH, C_{1-6} alkoxy, CN, $(C_m - alkylene)CONR^9R^{10}$, $(C_m - alkylene)CO_2R^8$, $(C_m - alkylene)S(O)_pR^{11}$, $(C_m - alkylene)SO_2NR^9R^{10}$ or a group of formula X-aryl or X-het, where X is a direct link,

20 $CH=CH$, $CH(OH)$, CO, OCH_2 , CH_2O or CH_2 .

Yet more preferably, R^6 is H, Br, methyl optionally substituted by OH, ethyl optionally substituted by OH, cyclopentyl optionally substituted by OH, cyclohexyl optionally substituted by OH, C_{1-6} alkoxy, CN, $O(C_n - alkylene)CN$, $(C_n - alkylene)CN$, SO_2R^{11} , SR^{11} , $CONR^9R^{10}$, CO_2R^8 , $SO_2NR^9R^{10}$, a group of formula X-(optionally substituted phenyl) or X-het¹,

25

where X is a direct link, $CH=CH$, $CH(OH)$, CO, OCH_2 , CH_2O or CH_2 ,

and where the phenyl moiety linked via X is optionally substituted by one or more halogen, C_{1-6} alkyl optionally substituted by one or more substituents independently selected from halogen and OH, C_{1-6} alkoxy optionally substituted by one or more halogen, or CO_2R^{13} ,

30 where "het¹" is an optionally benzo-fused dioxolyl, furyl, thienyl, imidazolyl,

or a partially or fully saturated analogue thereof,
and such "het¹" group linked via X being optionally substituted by one or more C₁₋₆ alkyl
optionally substituted by one or more substituents independently selected from halogen and
OH.

- 5 Further more preferably, R⁶ is H, Br, CO₂H, (E)CH=CHPh, Ph, OCH₃, 1,3-benzo[d]dioxol-5-yl, CN, CH₂OH, CONHBn, 4-methoxyphenyl, 1-hydroxycyclohexyl, 1-hydroxycyclopentyl, CPh, CH(OH)CH₃, CH(OH)Ph, CCH₃(OH)Ph, OCH₂Ph, SO₂Ph, SPh, CH₂OPh, SO₂NH₂, SO₂NHPh, SO₂NH(cyclopentyl), SO₂(pyrrolidino), SO₂(morpholino), SO₂(N-methylpiperazino), (2-methylimidazol-1-yl)methyl, (2-methylbenzimidazol-1-yl)methyl,
10 benzofuran-2-yl, thien-3-yl, thien-2-yl, 4-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3-carboxyphenyl, 3-cyanophenyl or 3-chlorophenyl.

- Most preferably, R⁶ is CH(OH)Ph, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,6-dimethoxyphenyl, SO₂NH₂, SO₂NHPh, SO₂NH(cyclopentyl), SO₂(pyrrolidino),
15 SO₂(morpholino), SO₂Ph, SPh, SO₂(N-methylpiperazino) or 3-carboxyphenyl.

Preferably, R⁷ is H.

- A preferred group of compounds is one in which R¹ is N=C(NH₂)₂ or NH(C(=NH)NH₂),
20 each of R², R⁴, R⁵ and R⁷ are H, R³ is Br or Cl, and R⁶ is 2-methoxyphenyl, 4-methoxyphenyl, CH(OH)Ph, SO₂Ph, SPh, 3-carboxyphenyl or 3-methoxyphenyl.

- Another preferred group of compounds are those in which two of R⁴, R⁵, R⁶ and R⁷ are
attached to adjacent carbon atoms, and are taken together to form a OCH₂O moiety,

- 25 Yet another preferred group are the compounds of the Examples, and the salts thereof.

The most preferred compounds are selected from:

- (4-chloro-7-(2-methoxyphenyl)isoquinolin-1-yl)guanidine;
30 (4-chloro-7-(3-methoxyphenyl)isoquinolin-1-yl)guanidine;

- (4-chloro-7-(4-methoxyphenyl)isoquinolin-1-yl)guanidine;
(4-chloro-7-(2,6-dimethoxyphenyl)isoquinolin-1-yl)guanidine;
(4-bromo-7-(3-methoxyphenyl)isoquinolin-1-yl)guanidine;
(4-bromo-7-(4-methoxyphenyl)isoquinolin-1-yl)guanidine;
5 (4-chloro-7-(α -hydroxybenzyl)isoquinolin-1-yl)guanidine;
(4-chloro-7-(3-carboxyphenyl)isoquinolin-1-yl)guanidine;
1-guanidino-7-sulphamoylisoquinoline;
1-guanidino-7-phenylsulphamoylisoquinoline;
4-chloro-1-guanidino-7-sulphamoylisoquinoline;
10 4-chloro-7-cyclopentylsulphamoyl-1-guanidinoisoquinoline;
4-chloro-1-guanidino-7-(1-pyrrolidinosulphonyl)isoquinoline hydrochloride;
4-chloro-1-guanidino-7-morpholinosulphonylisoquinoline hydrochloride;
4-chloro-1-guanidino-7-[(N-methylpiperazino)sulphonyl]isoquinoline;
4-chloro-1-guanidino-7-(phenylsulphanyl)isoquinoline;
15 4-chloro-1-guanidino-7-(phenylsulphonyl)isoquinoline;
and the salts thereof.

Another aspect of the invention is a pharmaceutical composition comprising a compound or salt according to the above definitions and a pharmaceutically-acceptable adjuvant, carrier or
20 diluent.

Yet another aspect of the invention is a compound or salt according to the above definitions for use as a medicament.

25 A further aspect of the invention is the use of a compound or salt according to the above definitions for the manufacture of a medicament for the treatment of a condition or process mediated by uPA, such as chronic dermal ulcer, angiogenesis (neo-vascularization), bone restructuring, embryo implantation in the uterus, infiltration of immune cells into inflammatory sites, ovulation, spermatogenesis, tissue remodelling during wound repair and

organ differentiation, fibrosis, local invasion of tumours into adjacent areas, metastatic spread of tumour cells from primary to secondary sites, and tissue destruction in arthritis.

Yet another aspect of the invention is a method of treatment of a condition or process

5 mediated by uPA, such as chronic dermal ulcer, angiogenesis (neo-vascularization), bone restructuring, embryo implantation in the uterus, infiltration of immune cells into inflammatory sites, ovulation, spermatogenesis, tissue remodelling during wound repair and organ differentiation, fibrosis, local invasion of tumours into adjacent areas, metastatic spread of tumour cells from primary to secondary sites, and tissue destruction in arthritis, comprising
10 administering a therapeutic amount of a compound or salt or composition according to the above definitions.

It is to be appreciated that reference to treatment includes prophylaxis as well as the alleviation of established symptoms of uPA-mediated conditions.


15 The invention further provides Methods for the production of compounds of the invention, which are described below and in the Examples. The skilled person will appreciate that the compounds of the invention could be made by methods other than those herein described, by adaptation of the methods herein described in the sections below and/or adaptation thereof, and
20 of methods known in the art.

In the Methods below, unless otherwise specified, the substituents are as defined above with reference to the compounds of formula (I) above.

25 Method 1

Compounds of formula (I) can be obtained from the corresponding 1- or 3-aminoisoquinoline derivative (II) as appropriate:

14




(II)

- by reaction with cyanamide (NH_2CN) or a reagent which acts as a " $\text{NHC}^+=\text{NH}$ " synthon such as carboxamidine derivatives, e.g. 1*H*-pyrazole-1-carboxamidine (M. S. Bernatowicz, Y. Wu, G. R. Matsueda, *J. Org. Chem.*, 1992, **57**, 2497), the 3,5-dimethylpyrazole analogue thereof (M.A.Brimble et al, *J.Chem.Soc.Perkin Trans.I* (1990)311), simple O-alkylthiouronium salts or S-alkylisothiouronium salts such as O-methylisothiurea (F.El-Fehail et al, *J.Med.Chem.*(1986), 29, 984), S-methylisothiouronium sulphate (S.Botros et al, *J.Med.Chem.*(1986)29,874; P. S. Chauhan et al, *Ind. J. Chem.*, 1993, **32B**, 858) or S-ethylisothiouronium bromide (M.L.Pedersen et al, *J.Org.Chem.*(1993) 58, 6966). Alternatively aminoiminomethanesulphinic acid, or aminoiminomethanesulphonic acid may be used (A.E.Miller et al, *Synthesis* (1986) 777; K.Kim et al, *Tet.Lett.*(1988) 29,3183).
- Other methods for this transformation are known to those skilled in the art (see for example, "Comprehensive Organic Functional Group Transformations", 1995, Pergamon Press, Vol 6 p639, T. L. Gilchrist (Ed.); Patai's "Chemistry of Functional Groups", Vol. 2. "The Chemistry of Amidines and Imidates", 1991, 488).
- Aminoisoquinolines (II) may be prepared by standard published methods (see for example, "The Chemistry of Heterocyclic Compounds" Vol. 38 Pt. 2 John Wiley & Sons, Ed. F. G. Kathawala, G. M. Coppolq, H. F. Schuster) including, for example, by rearrangement from the corresponding carboxy-derivative (Hoffmann, Curtius, Lossen, Schmidt-type rearrangements) and subsequent deprotection.
- Aminoisoquinolines (II) may alternatively be prepared by direct displacement of a leaving group such as Cl or Br with a nitrogen nucleophile such as azide (followed by reduction), or

by ammonia, or through Pd-catalysis with a suitable amine (such as benzylamine) followed by deprotection using standard conditions well-known in the art.

1-(Chloro or bromo)isoquinolines can be prepared by treatment of the corresponding N-oxides of formula (III) with POCl_3 or POBr_3 respectively in an inert solvent such as methylene chloride at reflux.




(III)

10 Haloisoquinolines are commercially available or can alternatively be prepared by various methods, for example those described in : Goldschmidt, *Chem.Ber.*(1895)**28**,1532; Brown and Plasz, *J.Het.Chem.*(1971)**6**,303; US Patent 3,930,837; Hall et al, *Can.J.Chem.*(1966)**44**,2473; White, *J.Org.Chem.*(1967)**32**,2689; and Ban, *Chem.Pharm.Bull.*(1964)**12**,1296.

15 1,4-(Dichloro- or dibromo)isoquinolines can be prepared by the method described by M.Robison et al in *J.Org.Chem.*(1958)**23**,1071, by reaction of the corresponding isocarbostyryl compound with PCl_5 or PBr_5 .

20 Method 2

Compounds of formula (I) can be obtained from the corresponding aminoisoquinoline derivative (II) as defined in Method 1 above, via reaction with a reagent which acts as a protected amidine(2+) synthon (IV),




such as a compound $\text{PNHC}(=\text{X})\text{NHP}_1$, $\text{PN}=\text{CXNHP}_1$ or $\text{PNHCX}=\text{NP}_1$, where X is a leaving group such as Cl, Br, I, mesylate, tosylate, alkyloxy, etc., and where P and P_1 may be the same or different and are N-protecting groups such as are well-known in the art, such as t-butoxycarbonyl, benzyloxycarbonyl, arylsulphonyl such as toluenesulphonyl, nitro, etc.

Examples of reagents that act as synthons (IV) include N, N'-protected-S-alkylthiuronium derivatives such as N, N'-bis(t-butoxycarbonyl)-S-Me-isothiurea, N, N'-bis(benzyloxycarbonyl)-S-methylisothiurea, or sulphonic acid derivatives of these (*J. Org. Chem.* 1986, 51, 1882), or S-arylthiuronium derivatives such as N, N'-bis(t-butoxycarbonyl)-S-(2,4-dinitrobenzene) (S. G. Lammin, B. L. Pedgrift, A. J. Ratcliffe, *Tet. Lett.* 1996, 37, 6815), or mono-protected analogues such as [(4-methoxy-2,3,6-trimethylphenyl)sulphonyl]-carbamimidothioic acid methyl ester or the corresponding 2,2,5,7,8-pentamethylchroman-6-sulphonyl analogue (D. R. Kent, W. L. Cody, A. M. Doherty, *Tet. Lett.*, 1996, 37, 8711), or S-methyl-N-nitroisothiurea (L. Fishbein et al, *J. Am. Chem. Soc.* (1954) 76, 1877) or various substituted thioureas such as N, N'-bis(t-butoxycarbonyl)thiourea (C. Levallet, J. Lerpiniere, S. Y. Ko, *Tet.* 1997, 53, 5291) with or without the presence of a promoter such as a Mukaiyama's reagent (Yong, Y.F.; Kowalski, J.A.; Lipton, M.A. *J. Org. Chem.*, 1997, 62, 1540), or copper, mercury or silver salts, particularly with mercury (II) chloride. Suitably N-protected O-alkylisoureas may also be used such as O-methyl-N-nitroisourea (N. Heyboer et al, *Rec. Chim. Trav. Pays-Bas* (1962) 81, 69). Alternatively other guanylation agents known to those skilled in the art such as 1-H-pyrazole-1-[N,N'-bis(t-butoxycarbonyl)]carboxamidine, the corresponding bis-Cbz derivative (M. S. Bernatowicz, Y. Wu, G. R. Matsueda, *Tet. Lett.* 1993, 34, 3389) or monoBoc or mono-Cbz derivatives may be used (B. Drake.. *Synthesis*, 1994, 579, M. S. Bernatowicz.. *Tet. Lett.* 1993, 34, 3389). Similarly, 3,5-dimethyl-1-nitroguanylpurazole may be used (T. Wakayima et al, *Tet. Lett.* (1986) 29, 2143).

The reaction can conveniently be carried out using a suitable solvent such as dichloromethane, N,N-dimethylformamide (DMF), methanol.

- 5 The reaction is also conveniently carried out by adding mercury (II) chloride to a mixture of the aminoisoquinoline (II) and a thiourea derivative of type (IV) in a suitable base / solvent mixture such as triethylamine / dichloromethane.



(V)

- 10 The product of this reaction is the protected isoquinolinylguanidine (V), which can conveniently be deprotected to give (I) or a salt thereof. For example, if the protecting group P and/or P₁ is t-butoxycarbonyl, conveniently the deprotection is carried out using an acid such as trifluoroacetic acid (TFA) or hydrochloric acid, in a suitable solvent such as dichloromethane, to give the bistrifluoroacetate salt of (I).

- 15 If P and/or P₁ is a hydrogenolysable group, such as benzyloxycarbonyl, the deprotection could be performed by hydrogenolysis.

Other protection / deprotection regimes include :


- 20 nitro (K.Suzuki et al, *Chem.Pharm.Bull.* (1985)33,1528, Nencioni et al, *J.Med.Chem.*(1991)34,3373, B.T.Golding et al, *J.C.S.Chem.Comm.*(1994)2613;
p-toluenesulphonyl (J.F.Callaghan et al, *Tetrahedron* (1993) 49 3479;
mesitylsulphonyl (Shiori et al, *Chem.Pharm.Bull.*(1987)35,2698, *ibid.*(1987)35,2561, *ibid.*,
(1989)37,3432, *ibid.*, (1987)35,3880, *ibid.*, (1987)35,1076;
25 2-adamantoyloxycarbonyl (Iuchi et al, *ibid.*, (1987) 35, 4307; and

methylsulphonylethoxycarbonyl (Filippov et al, *Syn.Lett.*(1994)922)

It will be apparent to those skilled in the art that other protection and subsequent deprotection regimes during synthesis of a compound of the invention may be achieved by conventional techniques, for example as described in "Protective Groups in Organic Synthesis" by T W
5 Greene and P G M Wuts, John Wiley and Sons Inc. (1991), and by P.J.Kocienski, in "Protecting Groups", Georg Thieme Verlag (1994).

Method 3

10 Compounds with the formula (I) where R¹ is guanidinyll and R² is H, or R¹ is H and R² is guanidinyll can be obtained from compounds of formula (VI):



(VI)

15 where Z is attached at the 1- or 3-position as appropriate and is a suitable leaving group such as Cl, Br or OPh, by displacement of the leaving group by the free base of guanidine.

The free base of guanidine may conveniently be generated *in situ* from a suitable salt, such as
20 the hydrochloride, carbonate, nitrate, or sulphate with a suitable base such as sodium hydride, potassium hydride, or another alkali metal base, preferably in a dry non-protic solvent such as tetrahydrofuran (THF), DMSO, N,N-dimethylformamide (DMF), ethylene glycol dimethyl ether (DME), N,N-dimethyl acetamide (DMA), toluene or mixtures thereof. Alternatively it can be generated from a suitable salt using an alkoxide in an alcohol solvent such as
25 potassium t-butoxide in t-butanol, or in a non-protic solvent as above.

The thus formed free guanidine can be combined with the 1- or 3-isoquinoline derivative, and the reaction to form compounds of formula (I) can be carried out at from room temperature to 200°C, preferably from about 50°C to 150°C, preferably for between 4 hours and 6 days.

5 Method 4

- Compounds of the formula (I) when one or more of R^{4-7} is or contains a hydroxy group, may be prepared from a suitably "protected" hydroxy derivative, i.e. a compound of the formula (I) where one or more of R^{4-7} is or contains "OP²", where P² is a suitable O-protecting group
- 10 such as O-benzyl. The benzyl group may be removed for example by catalytic hydrogenation using a palladium on charcoal catalyst in a suitable solvent such as ethanol at about 20°C and elevated pressure, optionally in the presence of an excess of an acid such as HCl or AcOH, or TFA, or by other known deprotection methods.
- 15 Suitable O-protecting groups and protection/deprotection can be found in the texts by Greene and Wuts, and Kocienski, *supra*.

Method 5

- 20 Compounds of the invention where R^4 - R^7 is or contains a carboxylic acid group or carbamoyl group can be made from the corresponding compound where the substituent is a nitrile by full or partial hydrolysis. Compounds of the invention where R^4 - R^7 is or contains a carboxylic acid group can be made from the corresponding compound where the substituent is a carbamoyl moiety, by hydrolysis. The hydrolysis can be carried out by methods well-known
- 25 in the art, for example those mentioned in "Advanced Organic Chemistry" by J. March, 3rd edition (Wiley-Interscience) chapter 6-5, and references therein. Conveniently the hydrolysis is carried out using concentrated hydrochloric acid, at elevated temperatures, and the product forms the hydrochloride salt.

30 Method 6

Where desired or necessary the compound of formula (I) is converted into a pharmaceutically acceptable salt thereof. A pharmaceutically acceptable salt of a compound of formula (I) may be conveniently be prepared by mixing together solutions of a compound of formula (I) and the
5 desired acid or base, as appropriate. The salt may be precipitated from solution and collected by filtration, or may be collected by other means such as by evaporation of the solvent.

General Methods of Interconversion

- 10 Compounds of the formula (I) where one or more of R^3 - R^7 is or contains Cl or Br may be dehalogenated to give the corresponding hydrido compounds of formula (I) by hydrogenolysis, suitably using a palladium on charcoal catalyst, in a suitable solvent such as ethanol at about 20°C and at elevated pressure.
- 15 Compounds of formula (I) where R^1 is guanidinyll and one or more of R^4 - R^7 is or contains a carboxy group may be prepared from a compound with a group hydrolysable to give a carboxy moiety, for example a corresponding nitrile or ester, by hydrolysis, for example by acidic hydrolysis with e.g. conc. aq. HCl at reflux. Other hydrolysis methods are well known in the art.
- 20 Compounds of formula (I) in which one or more of R^4 - R^7 contains an amide moiety may be made via reaction of an optionally protected corresponding carboxy compound, either by direct coupling with the amine of choice, or via initial formation of the corresponding acid chloride and subsequent reaction with the amine, followed by deprotection if appropriate.
- 25 Such transformations are well-known in the art.

Certain of the compounds of formula (I) which has an electrophilic group attached to an aromatic ring can be made by reaction of the corresponding hydrido compound with an electrophilic reagent.

For example sulphonylation of the aromatic ring using standard reagents and methods, such as fuming sulphuric acid, gives a corresponding sulphonic acid. This can then be optionally converted into the corresponding sulphonamide by methods known in the art, for example by firstly converting to the sulphonyl chloride followed by reaction with an amine.

5

Certain of the compounds of the invention can be made by cross-coupling techniques such as by reaction of a compound containing a bromo-substituent attached to e.g. an aromatic ring, with e.g. a boronic acid derivative, an olefin or a tin derivative by methods well-known in the art, for example by the methods described in certain of the Preparations below.

10

Certain of the compounds of the invention having an electrophilic substituent can be made via halogen/metal exchange followed by reaction with an electrophilic reagent. For example a bromo-substituent may react with a lithiating reagent such as n-butyllithium and subsequently an electrophilic reagent such as CO₂, an aldehyde or ketone, to give respectively an acid or an alcohol.

15

Compounds of the invention are available by either the methods described herein in the Methods and Examples or suitable adaptation thereof using methods known in the art. It is to be understood that the synthetic transformation methods mentioned herein may be carried out in various different sequences in order that the desired compounds can be efficiently assembled. The skilled chemist will exercise his judgement and skill as to the most efficient sequence of reactions for synthesis of a given target compound.

20

It will be apparent to those skilled in the art that sensitive functional groups may need to be protected and deprotected during synthesis of a compound of the invention. This may be achieved by conventional techniques, for example as described in "Protective Groups in Organic Synthesis" by T W Greene and P G M Wuts, John Wiley and Sons Inc. (1991), and by P.J.Kocienski, in "Protecting Groups", Georg Thieme Verlag (1994).

25

The compounds and salts of the invention may be separated and purified by conventional methods.

5 Separation of diastereomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or H.P.L.C. of a stereoisomeric mixture of a compound of formula (I) or a suitable salt or derivative thereof. An individual enantiomer of a compound of formula (I) may also be prepared from a corresponding optically pure intermediate or by resolution, such as by H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereomeric salts formed by reaction of the
10 corresponding racemate with a suitably optically active acid or base.

For human use, the compounds of formula (I) or their salts can be administered alone, but will generally be administered in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier selected with regard to the intended route of administration and standard
15 pharmaceutical practice. For example, they can be administered orally, including sublingually, in the form of tablets containing such excipients as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents. They can be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral
20 administration, they are best used in the form of a sterile aqueous solution or suspension which may contain other substances, for example, enough salt or glucose to make the solution isotonic with blood. They can be administered topically, in the form of sterile creams, gels, suspensions, lotions, ointments, dusting powders, sprays, drug-incorporated dressings or via a skin patch. For example they can be incorporated into a cream consisting of an aqueous or
25 oily emulsion of polyethylene glycols or liquid paraffin, or they can be incorporated into an ointment consisting of a white wax soft paraffin base, or as hydrogel with cellulose or polyacrylate derivatives or other viscosity modifiers, or as a dry powder or liquid spray or aerosol with butane/propane, HFA or CFC propellants, or as a drug-incorporated dressing either as a tulle dressing, with white soft paraffin or polyethylene glycols impregnated gauze
30 dressings or with hydrogel, hydrocolloid, alginate or film dressings. The compound or salt

could also be administered intraocularly as an eye drop with appropriate buffers, viscosity modifiers (e.g. cellulose derivatives), preservatives (e.g. benzalkonium chloride (BZK)) and agents to adjust tenicity (e.g. sodium chloride).

- 5 All such formulations may also contain appropriate stabilisers and preservatives.

For oral and parenteral administration to human patients, the daily dosage level of the compounds of formula (I) or their salts will be from 0.001 to 20, preferably from 0.01 to 20, more preferably from 0.1 to 10, and most preferably from 0.5 to 5 mg/kg (in single or divided
10 doses). Thus tablets or capsules of the compounds will contain from 0.1 to 500, preferably from 50 to 200, mg of active compound for administration singly or two or more at a time as appropriate.

The physician in any event will determine the actual dosage which will be most suitable for a
15 an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case; there can of course be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

- 20 It is to be appreciated that reference to treatment includes prophylaxis as well as the alleviation of established symptoms of the condition to be treated.

Test Methods

- 25 Compounds were tested for their ability to inhibit human urokinase, human tPA and human plasmin, using substantially the same methods as described by Yang, et al, *J.Med.Chem.*, (1990) 33, 2961. The urokinase assay was carried out using S-2444 (Quadratesch 820357) as substrate and the urokinase used was HMWT Human Urokinase (Calbiochem 672081). The tPA assay was carried out using S-2288 (Quadratesch 820832) tPA substrate,
30 Quadratesch 321116 as tPA stimulator, and the tPA used was Human tPA (Quadratesch 881157).

The plasmin assay was carried out using human plasmin (Quadrach 810665) acting on Chromozym-PL (Boehringer 378461) as substrate.

As shown below, the substances of the invention are selective uPA inhibitors:

5

Example No.	K_i uPA (nM)	vs. tPA*	vs. plasmin*
15	249	380	204
19	400	88	68
35	63	>1000	286.

10


*selectivity figures

Some of the compounds of the invention are named as derivatives of guanidine, and some as derivatives of isoquinoline.

EXAMPLES AND PREPARATIONS

Melting points were determined using a Gallenkamp melting point apparatus and are uncorrected. Nuclear magnetic resonance data were obtained using a Varian Unity 300 or
5 Varian Inova 400 spectrometer, and are quoted in parts per million from tetramethylsilane. Mass spectral data were obtained on a Finnigan Mat. TSQ 7000 or a Fisons Instruments Trio 1000. The calculated and observed ions quoted refer to the isotopic composition of lowest mass. Reference to "ether" in this section should be read as diethyl ether, unless specified otherwise. "Ph" represents the phenyl group, "Bn" represents the benzyl group and "Me"
10 represents the methyl group. "TLC" means thin layer chromatography. "TFA" represents trifluoroacetic acid.

Example 1: 1-Isoquinolinyguanidine



15 Sodium hydride (192 mg, 60 % dispersion in mineral oil, 4.8 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (465 mg, 4.9 mmol) in DMSO (6.0 mL) under nitrogen at room temperature, and the mixture was stirred until the evolution of
20 hydrogen had ceased. 1-Chloroisoquinoline (300 mg, 1.83 mmol) was added and the mixture was heated at 100°C for 3 days. The solvents were evaporated *in vacuo* and the residue directly purified by column chromatography upon silica gel using dichloromethane:methanol:ammonia 0.880 (95:5:0.5 to 90:10:1) as eluant to give 1-isoquinolinyguanidine (195 mg, 1.0 mmol) as a white solid.
25 M.Pt. 163-5°C;

¹H NMR (δ, DMSO-*d*₆, 400 MHz) 6.95 (1H, d), 7.4 (1H, dd), 7.55 (1H, dd), 7.65 (1H, d), 7.85 (1H, d), 8.55 (1H, d);

LRMS 187 (MH), 373 (M₂H);

Elemental Analysis: Found - C, 61.66; H, 5.37; N, 29.10. Calcd for C₁₀H₁₀N₄ + 0.45 H₂O -

5 C, 61.81; H, 5.65; N, 28.83.

Other compounds prepared by the same general method, using appropriate starting materials, are listed in Table 1 below.

Examples 2 and 3 were characterised as the corresponding hydrochloride salts, prepared by
10 addition of ethereal HCl to a solution of the free base and evaporation to dryness.

Examples 28 and 29 were characterised as the trifluoroacetate salts, prepared by dissolution of the free base in trifluoroacetic acid and evaporation to dryness.




Table I

(NB unless otherwise specified, substituents are H)

Ex.	R ³	R ^{4,7}	Rn. Condns. (a)	Mp °C	Elemental Analysis	LRMS	¹ H, δ
2 ^(c)	Cl	-	<i>t</i> - BuOH, 60°C, 4h	131-3	-	221, 223 (MH)	(DMSO- <i>d</i> ₆ + TFAD, 300 MHz) 7.85 (1H, dd), 8.0 (1H, dd), 8.15 (1H, d), 8.25 (1H, s), 8.5 (1H, d), 14.5-15.0 (4H, br s)
3 ^(d)	Br	-	<i>t</i> - BuOH, 90°C, 4h	165.5 -168	Found: C, 39.41; H, 3.12; N, 18.16. Calcd for C ₁₀ H ₉ BrN ₄ .HCl + 0.2 H ₂ O: C, 39.36; H, 3.43; N, 18.36.	265, 267 (MH)	(DMSO- <i>d</i> ₆ , 400 MHz) 7.1-7.5 (4H, br s), 7.6 (1H, dd), 7.8 (1H, dd), 7.85 (1H, d), 8.1 (1H, s), 8.7 (1H, d)
4 ^(e)	Me	-	100°C, 5 days	46-47	-	201 (MH)	(DMSO- <i>d</i> ₆ , 300 MHz) 2.4 (3H, s), 6.9-7.45 (4H, br s), 7.45 (1H, dd), 7.65 (1H, dd), 7.75 (1H, d), 7.8 (1H, s), 8.65 (1H, d)
5 ^(f)	-	5-Br	<i>t</i> - BuOH, reflux, 4 days	-	Found: C, 44.35; H, 3.31; N, 20.68. Calcd for C ₁₀ H ₉ BrN ₄ + 0.1 CH ₂ Cl ₂ : C, 44.34; H, 3.39; N, 20.48.	265, 267 (MH)	(CDCl ₃ , 300 MHz) 5.5-6.6 (4H, br s), 7.35 (1H, dd), 7.45 (1H, d), 7.85 (1H, d), 8.15 (1H, d), 8.7 (1H, d)
6 ^(g)	-	5-OMe	100°C, 3.5 days	182-4	Found: C, 60.07; H, 5.49; N, 25.27. Calcd for C ₁₁ H ₁₂ N ₄ O + 0.2 H ₂ O + 0.02 CH ₂ Cl ₂ : C, 59.80; H, 5.66; N, 25.32.	217 (MH)	(CDCl ₃ , 400 MHz) 3.95 (3H, s), 6.9 (1H, d), 7.35 (1H, dd), 7.45 (1H, d), 8.0 (1H, d), 8.25 (1H, d)

7	-	5-OBn	100°C, 2.5 days	208- 210	Found: C, 61.77; H, 5.17; N, 16.93. Calcd for C ₁₇ H ₁₆ N ₄ O + 0.2 H ₂ O + 0.5 CH ₂ Cl ₂ : C, 62.11; H, 5.18; N, 16.56	293 (MH)	(DMSO- <i>d</i> ₆ , 400 MHz) 5.3 (2H, s), 7.3-7.4 (4H, m), 7.5 (2H, d), 7.65 (1H, dd), 7.75 (1H, d), 8.15 (1H, d), 8.3 (1H, d)
8	-	5-OCH ₂ - CONH ₂	reflux, 4 days	>200	-	260 (MH)	(DMSO- <i>d</i> ₆ , 400 MHz) 4.55 (2H, s), 7.0 (1H, d), 7.2-7.8 (8H, br m), 7.95 (1H, d), 8.2 (1H, d)
9	-	5-CH ₂ OH	100°C, 3.5 days	177-9	Found: C, 56.84; H, 5.23; N, 23.28. Calcd for C ₁₁ H ₁₂ N ₄ O + 0.44 H ₂ O + 0.15 CH ₂ Cl ₂ : C, 56.53; H, 5.61; N, 23.65	217 (MH)	(DMSO- <i>d</i> ₆ , 400 MHz) 4.8 (2H, s), 5.2 (1H, br s), 7.0-7.65 (4H, br m), 7.65 (1H, d), 7.95 (1H, d), 8.5 (1H, d)
10	-	5-CONH ₂	100°C, 3.5 days	198	Found: C, 50.28; H, 4.91; N, 26.50. Calcd for C ₁₁ H ₁₁ N ₅ O + 1.3 H ₂ O + 0.16 CH ₂ Cl ₂ : C, 50.34; H, 5.27; N, 26.30	230 (MH), 459 (M ₂ H)	(MeOH- <i>d</i> ₄ , 400 MHz) 6.1 (1H, dd), 6.15 (1H, d), 6.35 (1H, d), 6.6 (1H, d), 7.05 (1H, d)
11	-	5-Ph	100°C, 3.5 days	73-5	Found: C, 69.58; H, 5.35; N, 20.46. Calcd for C ₁₆ H ₁₄ N ₄ + 0.7 H ₂ O + 0.02 CH ₂ Cl ₂ : C, 69.56; H, 5.63; N, 20.25.	263 (MH), 525 (M ₂ H)	(DMSO- <i>d</i> ₆ , 400 MHz) 6.85 (1H, d), 7.0-7.6 (11H, m), 7.85 (1H, d), 8.65 (1H, d)
12	-	5-SO ₂ NH ₂	100°C, 3 days	>220	Found: C, 44.78; H, 4.13; N, 25.42. Calcd for C ₁₀ H ₁₁ N ₅ O ₂ S + 0.25 H ₂ O + 0.06 MeOH: C, 44.47; H, 4.36; N, 25.77.	266 (MH)	(DMSO- <i>d</i> ₆ , 400 MHz) 7.0-7.4 (4H, br s), 7.45-7.5 (3H, m), 7.55 (1H, d), 8.0 (1H, d), 8.1 (1H, d), 8.9 (1H, d)

13	-	6-Br	100°C, 3 days	144-6	Found: C, 44.15; H, 3.48; N, 20.01. Calcd for C ₁₀ H ₉ BrN ₄ + 0.3 H ₂ O + 0.05 CH ₂ Cl ₂ : C, 43.93; H, 3.56; N, 20.39.	265, 267 (MH)	(DMSO- <i>d</i> ₆ , 300 MHz) 6.95 (1H, d), 6.95-7.4 (4H, br s), 7.55 (1H, d), 7.9-8.0 (2H, m), 8.5 (1H, d)
14	-	6-Me	120°C, 6 days	80 dec.	-	201 (MH)	(DMSO- <i>d</i> ₆ , 300 MHz) 7.1 (1H, d), 7.4 (1H, d), 7.55 (1H, s), 7.0-8.4 (4H, br s), 7.95 (1H, d), 8.55 (1H, d)
15	-	7-Br	reflux, 3 days	198- 200	Found: C, 44.29; H, 3.29; N, 20.42. Calcd for C ₁₀ H ₉ BrN ₄ + 0.1 CH ₂ Cl ₂ : C, 44.34; H, 3.39; N, 20.48.	265 (MH)	(CDCl ₃ , 400 MHz) 5.3-6.8 (4H, br s), 7.05 (1H, d), 7.5 (1H, d), 7.65 (1H, d), 8.05 (1H, d), 8.9 (1H, s)
16 ^(h)	-	7-OMe	95°C, 2 days	-	-	217 (MH), 433 (M ₂ H)	(DMSO- <i>d</i> ₆ , 300 MHz) 3.8 (3H, s), 7.0-7.5 (6H, m), 7.6 (1H, d), 7.8 (1H, d), 8.0 (1H, s)
17	-	7-Ph	100°C, 50h	-	-	263 (MH)	(DMSO- <i>d</i> ₆ , 400 MHz) 7.0-7.45 (6H, br m), 7.45-7.55 (2H, m), 7.7-7.8 (3H, m), 7.9-8.0 (2H, m), 8.95 (1H, s)
18	-	7-(3,4- OCH ₂ O- Ph)	90°C, 40h	-	-	307 (MH), 613 (M ₂ H)	(DMSO- <i>d</i> ₆ , 400 MHz) 6.0 (2H, s), 7.0 (2H, m), 7.2 (1H, d), 7.25 (1H, s), 7.65-7.75 (1H, m), 7.8-7.9 (2H, m), 8.75 (1H, s)
19	-	7- <i>E</i> -styryl	100°C, 5 days	211-3	Found: C, 72.63; H, 5.66; N, 18.62. Calcd for C ₁₈ H ₁₆ N ₄ + 0.5 H ₂ O: C, 72.71; H, 5.76; N, 18.84.	289 (MH)	(DMSO- <i>d</i> ₆ , 300 MHz) 7.0-7.45 (10H, m), 7.6-7.75 (3H, m), 7.85-8.0 (2H, m), 8.65 (1H, s)

20	-	7-OBn	100°C, 5 days	203-7	-	293 (MH)	(MeOH- <i>d</i> ₄ , 300 MHz) 5.3 (2H, s), 7.3-7.4 (3H, m), 7.5-7.6 (4H, m), 7.8-7.95 (2H, m), 8.1 (1H, d)
21	-	7-CN	100°C, 17h	204-5	Found: C, 59.13; H, 4.18; N, 30.25. Calcd for C ₁₁ H ₉ N ₅ + 0.21 CH ₂ Cl ₂ : C, 58.78; H, 4.15; N, 30.57.	212 (MH)	(DMSO- <i>d</i> ₆ , 400 MHz) 7.0 (1H, d), 7.0-7.5 (4H, br s), 7.75 (1H, d), 7.8 (1H, d), 8.0 (1H, d), 8.95 (1H, s)
22	-	7-CH ₂ OH	100°C, 48h	>220	-	217 (MH)	(DMSO- <i>d</i> ₆ , 300 MHz) 4.7 (2H, d), 5.25 (1H, t), 7.6 (1H, d), 7.85 (1H, d), 8.0 (1H, d), 8.0-9.4 (4H, br s), 8.15 (1H, d), 8.65 (1H, s)
23	-	7-CH ₂ OPh	80°C, 17h	<60	-	293 (MH)	(DMSO- <i>d</i> ₆ , 300 MHz) 5.3 (2H, s), 6.95 (1H, dd), 7.1 (2H, d), 7.25 (2H, dd), 7.6 (1H, d), 7.9 (1H, d), 8.05 (1H, d), 8.15 (1H, d), 8.9 (1H, s), 8.2-9.2 (4H, br s)
24	-	7-CH ₂ -(2-Me-1-H-imidazol-1-yl)	80°C, 28h	232-4	Found: C, 63.10; H, 5.67; N, 28.85. Calcd for C ₁₅ H ₁₆ N ₆ + 0.4 H ₂ O: C, 62.66; H, 5.89; N, 29.23.	281 (MH)	(DMSO- <i>d</i> ₆ + TFAD, 400 MHz) 2.6 (3H, s), 5.5 (2H, s), 7.55-7.65 (3H, m), 7.7 (1H, d), 8.0 (1H, d), 8.15 (1H, d), 8.4 (1H, s)
25	-	7-CH ₂ -(2-Me-1-H-benzimidazol-1-yl)	95°C, 26h	245-7	Found: C, 66.63; H, 6.19; N, 22.37. Calcd for C ₁₉ H ₁₈ N ₆ + 0.5 H ₂ O + 0.6 <i>i</i> -PrOH: C, 66.54; H, 6.39; N, 22.38.	331 (MH), 661 (M ₂ H)	(DMSO- <i>d</i> ₆ , 400 MHz) 2.9 (3H, s), 5.85 (2H, s), 7.4-7.6 (3H, m), 7.65 (1H, d), 7.7-7.8 (2H, m), 7.95 (1H, d), 8.15 (1H, d), 8.55 (1H, s)
26	-	7-CONHBn	100°C, 2 days	148- 151	-	320 (MH)	(MeOH- <i>d</i> ₄ , 300 MHz) 4.65 (2H, s), 4.8 (5H, br s), 7.2-7.45 (6H, m), 7.8 (1H, dd), 8.0-8.15 (2H, m), 9.0 (1H, s)

27	-	7- CH(OH)- Ph	94°C, 8.5h	163-5	Found: C, 63.43; H, 5.39; N, 17.49. Calcd for C ₁₇ H ₁₆ N ₄ O + 0.37 CH ₂ Cl ₂ + 0.2 H ₂ O; C, 63.73; H, 5.28; N, 17.11.	293 (MH)	(MeOH- <i>d</i> ₄ , 400 MHz) 5.9 (1H, s), 7.1-7.3 (4H, m), 7.35 (2H, d), 7.6 (1H, d), 7.65 (1H, d), 8.0 (1H, d), 8.5 (1H, s)
28	-	7- CH(OH)- Me	95°C, 2.5 days	-	Found C, 47.78; H, 4.21; N, 15.94. Calcd for C ₁₂ H ₁₄ N ₄ O + 1.1 TFA): C, 47.95; H, 4.28; N, 15.75.	231 (MH)	(TFAD, 400 MHz) 1.4 (3H, d), 4.9 (1H, m), 7.55 (1H, d), 7.8 (1H, d), 7.9 (1H, d), 8.1 (1H, d), 8.3 (1H, s)
29 ^(b)	-	7-COPh	94°C, 3 days	108 dec.	Found: C, 55.22; H, 4.15; N, 13.36. Calcd for C ₁₇ H ₁₄ N ₄ O + 0.5 H ₂ O +TFA : C, 55.21; H, 3.90; N, 13.55.	291 (MH)	(TFAD, 400 MHz) 7.2 (2H, dd), 7.7 (1H, dd), 7.75 (2H, d), 8.15 (1H, d), 8.25 (1H, d), 8.35 (1H, d), 8.45 (1H, d), 8.9 (1H, s)
30	-	7- C(Me)OH- Ph	95°C, 2.5 days	118 dec.	Found: C, 63.82; H, 5.80; N, 16.31. Calcd for C ₁₈ H ₁₈ N ₄ O + 0.48 CH ₂ Cl ₂ : C, 63.94; H, 5.57; N, 16.14.	307 (MH)	(MeOH- <i>d</i> ₄ , 400 MHz) 2.0 (3H, s), 4.8 (5H, br s), 7.0-7.3 (4H, m), 7.4 (2H, d), 7.55 (1H, d), 7.6 (1H, d), 8.0 (1H, d), 8.6 (1H, s)
31	-	7-(1- hydroxy- cyclopent- yl)	100°C, 14h	197-8	-	271 (MH)	(MeOH- <i>d</i> ₄ , 300 MHz) 0.4-0.8 (8H, m), 5.8 (1H, d), 6.3 (1H, d), 6.4 (1H, d), 6.55 (1H, d), 7.1 (1H, s)

32	-	7-(1-hydroxycyclohexyl)	100°C, 16h	186.5 -188	Found: C, 55.64; H, 6.08; N, 15.25. Calcd for C ₁₆ H ₂₀ N ₄ O + 1 CH ₂ Cl ₂ : C, 55.29; H, 6.00; N, 15.17.	285 (MH)	(MeOH- <i>d</i> ₄ , 300 MHz) 1.2-2.0 (10H, m), 7.15 (1H, d), 7.7 (1H, d), 7.85 (1H, d), 8.0 (1H, d), 8.6 (1H, s)
33	Cl	7-Br	100°C, 18h	218- 220 dec.	Found: C, 40.02; H, 2.75; N, 17.78. Calcd for C ₁₀ H ₈ BrClN ₄ + 0.3 MeOH: C, 40.01; H, 3.00; N, 18.12.	299, 301 (MH)	(DMSO- <i>d</i> ₆ , 300 MHz) 6.8-7.4 (4H, br s), 7.75 (1H, d), 7.85 (1H, d), 8.0 (1H, s), 8.8 (1H, s)
34	Cl	7-(4-Me-Ph)	100°C, 4 days	198- 200	Found: C, 61.38; H, 4.59; N, 16.74. Calcd for C ₁₇ H ₁₅ ClN ₄ + 0.34 CH ₂ Cl ₂ : C, 61.32; H, 4.65; N, 16.49.	311, 313 (MH)	(DMSO- <i>d</i> ₆ , 300 MHz) 2.35 (3H, s), 6.9-7.3 (4H, br s), 7.3 (2H, d), 7.65 (2H, d), 7.9 (1H, d), 7.95 (1H, s), 8.05 (1H, d), 8.95 (1H, s)
35	Cl	7-(2-MeO-Ph)	100°C, 40 h	-	-	327, 329 (MH)	(DMSO- <i>d</i> ₆ , 300 MHz) 3.75 (3H, s), 7.0-7.45 (8H, m), 7.85 (2H, br s), 8.0 (1H, s), 8.7 (1H, s)
36	Cl	7-(3-MeO-Ph)	100°C, 40 h	155-6	Found: C, 59.83; H, 4.45; N, 16.63. Calcd for C ₁₇ H ₁₅ ClN ₄ O + 0.6 H ₂ O + 0.05 CH ₂ Cl ₂ : C, 59.91; H, 4.81; N, 16.39.	327, 301 (MH)	(DMSO- <i>d</i> ₆ , 300 MHz) 3.8 (3H, s), 7.0 (1H, d), 7.15-7.4 (4H, br s), 7.25 (1H, s), 7.3 (1H, d), 7.45 (1H, dd), 7.95 (1H, d), 8.0 (1H, s), 8.1 (1H, d), 8.95 (1H, s)
37	Cl	7-(4-MeO-Ph)	100°C, 2.5 days	192-4	Found: C, 60.94; H, 4.51; N, 16.72. Calcd for C ₁₇ H ₁₅ ClN ₄ O + 0.4 H ₂ O: C, 61.14; H, 4.77; N, 16.77.	327, 329 (MH)	(DMSO- <i>d</i> ₆ , 400 MHz) 3.75 (3H, s), 7.0 (2H, d), 7.0-7.4 (4H, br s), 7.65 (2H, d), 7.85 (1H, d), 7.9 (1H, s), 8.0 (1H, d), 8.85 (1H, s)

38	Cl	7-(3,5-dimethoxy-Ph)	100°C, 18 h	210-212	Found: C, 59.98; H, 4.73; N, 15.53. Calcd for $C_{18}H_{17}ClN_4O_2 + 0.02 MeOH + 0.02 CH_2Cl_2$: C, 60.33; H, 4.80; N, 15.60.	357, 359 (MH)	(DMSO- d_6 , 400 MHz) 3.8 (6H, s), 6.5 (1H, s), 6.8 (2H, s), 6.9-7.4 (4H, br s), 7.85 (1H, d), 7.9 (1H, s), 8.05 (1H, d), 8.9 (1H, s)
39	Cl	7-(2,6-dimethoxy-Ph)	90°C, 18 h	130-136	Found C, 57.84; H, 5.14; N, 14.46. Calcd for $C_{18}H_{17}ClN_4O_2 + 0.25 diethyl ether + water$: C, 58.02; H, 5.51; N, 14.24	357, 359 (MH)	(DMSO- d_6 , 300 MHz) 8.5 (1H, s), 8.15-7.8 (2H, m), 7.8-7.0 (5H, m), 7.35 (1H, t), 6.75 (2H, d), 3.6 (6H, s)
40	Cl	7-(3,4-OCH ₂ O-Ph)	90°C, 19 h	-	Found: C, 55.32; H, 3.89; N, 14.90. Calcd for $C_{17}H_{13}ClN_4O_2 + 0.5 H_2O + 0.3 CH_2Cl_2$: C, 55.37; H, 3.92; N, 14.93.	341, 343 (MH)	(MeOH- d_4 , 300 MHz) 4.6 (2H, s), 5.5 (1H, d), 5.8-5.9 (2H, m), 6.5-6.65 (3H, m), 7.3 (1H, s)
41	Cl	7-(3-CN-Ph)	100°C, 18h	>220 °C	Found C, 59.85; H, 3.90; N, 19.94. Calcd for $C_{17}H_{12}ClN_5 + 0.8 water + 0.1 CH_2Cl_2$: C, 59.59; H, 4.04; N, 20.32	322 (MH), 339 (M+NH ₄)	(DMSO- d_6 , 300 MHz) 8.95 (1H, s), 8.15 (1H, s), 8.1 (1H, d), 8.05 (1H, d), 7.95 (1H, s), 7.9 (1H, d), 7.85 (1H, d), 7.7 (1H, t)
42	Cl	7-(3-thienyl)	100°C, 2.5 days	211-3	Found: C, 54.21; H, 3.66; N, 17.73. Calcd for $C_{14}H_{11}ClN_4S + 0.3 MeOH + 0.07 CH_2Cl_2$: C, 54.22; H, 3.91; N, 17.60.	303, 305 (MH)	(DMSO- d_6 , 400 MHz) 6.9-7.3 (4H, br s), 7.5-7.7 (2H, m), 7.8-8.0 (3H, m), 8.05 (1H, d), 8.9 (1H, s)

43	Cl	7-(2-benzo-furanyl)	100°C, 18 h	>220	Found: C, 62.94; H, 3.78; N, 16.20. Calcd for C ₁₈ H ₁₃ ClN ₄ O + 0.3 H ₂ O + 0.03 CH ₂ Cl ₂ : C, 62.82; H, 3.99; N, 16.25.	337, 339 (MH)	(DMSO- <i>d</i> ₆ , 400 MHz) 7.0-7.4 (4H, br s), 7.25 (1H, dd), 7.3 (1H, dd), 7.45 (1H, s), 7.6 (1H, d), 7.65 (1H, d), 7.9 (1H, d), 7.95 (1H, s), 8.25 (1H, d), 9.1 (1H, s)
44	Cl	7- CH(OH)- Ph	100°C, 8h	221.5 -223	Found: C, 60.87; H, 4.83; N, 16.01. Calcd. for C ₁₇ H ₁₅ ClN ₄ O + 0.6 H ₂ O + 0.1 <i>i</i> -Pr ₂ O: C, 60.78; H, 5.10; N, 16.11.	327, 329 (MH)	(MeOH- <i>d</i> ₄ , 300 MHz) 5.95 (1H, s), 7.2-7.35 (3H, m), 7.4 (2H, d), 7.7 (1H, d), 7.95 (1H, d), 8.0 (1H, s), 8.65 (1H, s)
45	Br	7-Br	100°C, 2 days	-	Found: C, 34.88; H, 2.27; N, 16.01. Calcd for C ₁₀ H ₈ Br ₂ N ₄ + 0.06 CH ₂ Cl ₂ : C, 34.61; H, 2.34; N, 16.05.	345 (MH)	(DMSO- <i>d</i> ₆ , 400 MHz) 6.8-7.4 (4H, br s), 7.7 (1H, d), 7.85 (1H, d), 8.05 (1H, s), 8.8 (1H, s)
46	Br	7-Ph	100°C, 3 days	205-7	Found: C, 55.43; H, 3.73; N, 16.01. Calcd for C ₁₆ H ₁₃ BrN ₄ + 0.1 CH ₂ Cl ₂ : C, 55.30; H, 3.80; N, 16.02.	342 (MH)	(DMSO- <i>d</i> ₆ , 300 MHz) 7.0-7.4 (4H, br s), 7.4 (1H, dd), 7.5 (2H, dd), 7.75 (2H, d), 7.85 (1H, d), 8.0 (1H, d), 8.05 (1H, s), 8.95 (1H, s)
47	Br	7-(4-Me- Ph)	100°C, 18h	203-5	Found: C, 55.09; H, 4.11; N, 14.79. Calcd for C ₁₇ H ₁₅ BrN ₄ + 0.5 H ₂ O + 0.11 CH ₂ Cl ₂ : C, 55.01; H, 4.38; N, 15.00.	355, 357 (MH), 711 (M ₂ H)	(DMSO- <i>d</i> ₆ , 400 MHz) 2.3 (3H, s), 6.8-7.4 (6H, m), 7.6 (2H, d), 7.8 (1H, d), 8.0-8.05 (2H, m), 8.9 (1H, s)

48	Br	7-(3-MeO-Ph)	100°C, 18h	148-150	Found: C, 53.29; H, 3.99; N, 14.33. Calcd. for $C_{17}H_{15}BrN_4O + 0.2 CH_2Cl_2$: C, 53.21; H, 4.00; N, 14.43.	371, 373 (MH)	(DMSO- d_6 , 400 MHz) 3.8 (3H, s), 6.95 (1H, d), 7.0-7.3 (4H, br s), 7.2 (1H, s), 7.25 (1H, d), 7.4 (1H, dd), 7.8 (1H, d), 8.0-8.05 (2H, m), 8.9 (1H, s)
49	Br	7-(4-MeO-Ph)	100°C, 18h	195-7	Found: C, 53.89; H, 3.98; N, 14.59. Calcd. for $C_{17}H_{15}BrN_4O + 0.1 H_2O + 0.1 CH_2Cl_2$: C, 53.83; H, 4.07; N, 14.68.	371, 373 (MH)	(DMSO- d_6 , 400 MHz) 3.75 (3H, s), 7.05 (2H, d), 6.9-7.3 (4H, br s), 7.65 (2H, d), 7.8 (1H, d), 8.0 (1H, d), 8.0 (1H, s), 8.85 (1H, s)
50	Br	7-(3-Cl-Ph)	100°C, 18h	183-5	Found: C, 50.56; H, 3.21; N, 14.41. Calcd. for $C_{16}H_{12}BrClN_4 + 0.1 EtOAc + 0.06 CH_2Cl_2$: C, 50.75; H, 3.34; N, 14.38.	375, 377, 379 (MH)	(DMSO- d_6 , 300 MHz) 7.0-7.3 (4H, br s), 7.45 (1H, d), 7.5 (1H, dd), 7.7 (1H, d), 7.75 (1H, s), 7.8 (1H, d), 8.05 (1H, d), 8.1 (1H, s), 8.95 (1H, s)
51	-	6,7-OCH ₂ O-	100°C, 5 days	171 dec	-	231 (MH)	(DMSO- d_6 , 300 MHz) 6.1 (2H, s), 7.0 (1H, d), 7.1 (1H, s), 7.0-7.5 (4H, br s), 7.8 (1H, d), 7.9 (1H, s)

(a) Solvent DMSO unless otherwise specified.

(b) Isolated as a byproduct during the preparation of Example 27.

(c) [References (c) to (h) relate to preparations of starting materials.]

(d) Robison, M.M.; Robison, B.L. *J. Org. Chem.* 1958, **23**, 1071.


(e) Sanders, G.M.; van Dijk, M.; den Hertog, H.J. *Recl. Trav. Chim. Pays-Bas.* 1974, **93**, 298.

(f) Eloy, F.; Deryckere *Helv. Chim. Acta.* 1969, **52**, 1755.

(g) Braye, R.; Eloy, F.; Hoogzand, C.; Lenaers, R. *Eur. J. Med. Chem., Chim. Therap.* 1974, **9**, 197.

(h) Copp, F.C.; Franzmann, K.W.; Grundy, J.; Whalley, W.B. *J. Chem. Soc., Perkin Trans. I*, 1985, 2455.

(b) Bevis, M.J.; Forbes, E.J.; Naik, N.N.; Uff, B.C. *Tetrahedron*, 1971, **27**, 1253.

Example 52: 3-Isoquinolinyguanidine and the bis(trifluoroacetate) salt thereof


5 Mercury (II) chloride (192 mg, 0.707 mmol) was added in one portion to a stirred mixture of 3-aminoisoquinoline (84.5 mg, 0.586 mmol), *N,N'*-di-*t*-butoxycarbonyl-*S*-methylothiourea (Bergeron, R. J.; McManis, J. S. *J. Org. Chem.* **1987**, *52*, 1700-1703) (204 mg, 0.703 mmol), and triethylamine (250 μ L, 1.79 mmol) in CH_2Cl_2 (3.0 mL) under N_2 at 23°C. The mixture was stirred for 26 hours and then directly purified by column chromatography upon silica gel
10 using hexanes-EtOAc (98:2 to 95:5) as eluant to give 3-(*N',N''*-di-*t*-butoxycarbonyl-*N*-guanidinyloisoquinoline (189.4 mg, 0.492 mmol) as a white solid.

^1H NMR (δ , CDCl_3 , 300 MHz) 1.55 (18, s), 7.45 (1H, dd), 7.65 (1H, dd), 7.85-7.9 (2H, m), 8.7 (1H, br s), 9.0 (1H, s), 10.5 (1H, br s), 11.6 (1H, br s);
LRMS 387 (MH).

15 Trifluoroacetic acid (2.5 mL) was added to a solution of 3-(*N',N''*-di-*t*-butoxycarbonyl-*N*-guanidinyloisoquinoline (181 mg, 0.468 mmol) in CH_2Cl_2 (1.5 mL) and the mixture was stirred at room temperature for 2 h. The mixture was diluted with CH_2Cl_2 (5 mL) and the solvents were evaporated *in vacuo* to yield 3-isoquinolinyguanidine bis(trifluoroacetate)
20 (186.9 mg, 0.449 mmol) as a white solid.

^1H NMR (δ , $\text{MeOH}-d_4$, 400 MHz) 4.8-5.0 (4H, br s), 7.4 (1H, s), 7.6 (1H, dd), 7.75 (1H, dd), 7.85 (1H, d), 8.05 (1H, d), 9.1 (1H, s);
LRMS 187 (MH);

Elemental Analysis: Found: C, 40.46; H, 2.77; N, 13.36. Calcd for $\text{C}_{10}\text{H}_{10}\text{N}_4 + 2\text{TFA}$: C, 40.59; H, 2.92; N, 13.52.
25

Example 53 : (5-Hydroxyisoquinolin-1-yl)guanidine

5

A solution of (5-benzyloxyisoquinolin-1-yl)guanidine (290 mg, 1.0mmol) in EtOH (10 mL) containing 10% Pd-C (60 mg) and dilute HCl (1.5 mL, 2 M, 3.0 mmol) was stirred under an atmosphere of H₂ (4 atmospheres) at 60°C for 3 d. An additional portion of catalyst (30 mg) and HCl (0.5 mL) were added and hydrogenation continued for a further 3 d. The mixture
10 was filtered through Arbocel with EtOH rinsing, the filtrate was evaporated *in vacuo* and the residue purified by column chromatography upon silica gel using dichloromethane:methanol:0.88 ammonia (90:10:1 to 84:14:2) as eluant to give (5-hydroxyisoquinolin-1-yl)guanidine (66 mg, 0.33 mmol) as a white solid.


M.Pt. >150°C dec.;

15 ¹H NMR (δ, DMSO-*d*₆, 400 MHz) 3.0-3.4 (1H, br s), 7.05 (1H, d), 7.35 (1H, dd), 7.4-8.4 (3H, br s), 7.45 (1H, br s), 7.95 (1H, d), 8.1 (1H, d), 10.5-11.0 (1H, br s);

LRMS 203 (MH);

Elemental Analysis: Found: C, 52.00; H, 5.35; N, 23.00. Calculated for

C₁₀H₁₀N₄O+0.66H₂O+0.3CH₂Cl₂: C, 51.64; H, 5.01; N, 23.38.


Example 54 : (7-(4-Methoxyphenyl)isoquinolin-1-yl)guanidine

- 5 A solution of (4-bromo-7-(4-methoxyphenyl)isoquinolin-1-yl)guanidine (38 mg, 0.1 mmol) in industrial methylated spirits (2.0 mL) containing 5% Pd-C (10 mg) was stirred under an atmosphere of H₂ (3.5 atmospheres) at 23°C for 3 days. The mixture was filtered through ArbocelTM with ethanol rinsing, the filtrate was evaporated *in vacuo* and the residue was purified by column chromatography on silica gel using dichloromethane:methanol:0.88 ammonia (97:3:0.3) as eluant to give (7-(4-methoxyphenyl)isoquinolin-1-yl)guanidine (24 mg, 0.08 mmol) as a white solid.

M.Pt. 174°C ;

¹H NMR (δ, DMSO-*d*₆, 400 MHz) 3.25 (4H, br s, exchangeable), 3.8 (3H, br s), 7.05 (2H, d), 7.5-7.6 (1H, m) 7.85 (2H, d), 8.0 (1H, d), 8.05-8.15 (2H, m), 8.75 (1H, s);

- 15 LRMS 293 (MH).

Example 55 : (7-(3-Carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine hydrochloride

A solution of (4-chloro-7-(cyanophenyl)isoquinolin-1-yl)guanidine (69 mg, 0.21 mmol) in concentrated hydrochloric acid (10 ml) was heated to reflux for 20 hours. After cooling, the

precipitate was filtered off, washed with water and dried under high vacuum at 80°C to afford the title salt (55mg, 0.16 mmol) as an off-white powder.


M.Pt. 312-316°C;

¹H NMR (δ, DMSO-d₆, 300 MHz) 13.4-11.2 (1H, br s), 9.4-7.8 (5H, br s), 9.2 (1H, s), 8.45-8.1 (5H, m), 8.0 (1H, d), 7.65 (1H, t);

LRMS 341, 343 (MH);

Elemental Analysis - Found: C, 53.25; H, 3.80; N, 14.28. Calcd for C₁₇H₁₄Cl₂N₄O₂ + 0.33 H₂O: C, 53.29; H, 3.86; N, 14.62.

10 Example 56: (i) 1-Guanidino-7-sulphamoylisoquinoline



Guanidine hydrochloride (42 mg, 0.44 mmol) was added in one portion to a suspension of NaH (13 mg, 80% dispersion by wt in mineral oil, 0.43 mmol) in DMSO (1.5 mL) and the mixture was heated at 60 °C under N₂ for 30 min. 1-Chloro-7-isoquinolinesulphonamide (37 mg, 0.152 mmol) was added and the mixture heated at 100 °C for 24 h. The solvents were evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (97:3:0.3 to 90:10:1) as eluant to give the title compound (34 mg, 0.13 mmol) as an off-white solid.

20 mp 198-200 °C (dec).

¹H (DMSO-d₆, 400 MHz) δ 7.0 (1H, d), 7.1-7.4 (4H, br s), 7.3 (2H, s), 7.8 (1H, d), 7.9 (1H, d), 8.0 (1H, d), 9.1 (1H, s) ppm.

LRMS 266 (MH⁺).


Anal. Found: C, 41.38; H, 3.97; N, 24.09. Calc for C₁₀H₁₁N₅O₂S•0.05CH₂Cl₂•1.1H₂O: C, 41.72; H, 4.63; N, 24.20.

(ii) 1-Guanidino-7-sulphamoylisoquinoline dihydrochloride

1-Guanidino-7-sulphamoylisoquinoline (12 mg, 0.045 mmol) was dissolved in a solution of ethanol saturated with HCl gas (1.0 mL) and the mixture was stirred at room temperature for 1 hour. The solvents were evaporated *in vacuo* and the residue was azeotroped with dichloromethane (CH₂Cl₂) to give 1-guanidino-7-sulphamoylisoquinoline dihydrochloride (13 mg, 0.043 mmol) as a white solid.

¹H (DMSO-*d*₆, 400 MHz) δ 7.6 (2H, s), 7.7 (1H, d), 8.2 (1H, s), 8.2 (1H, d), 8.3 (1H, d), 8.4-9.0 (4H, br s), 9.1 (1H, d), 11.0 (1H, s) ppm.

Found: C, 34.80; H, 3.85; N, 19.68. Calc for C₁₀H₁₁N₅O₂S•2HCl•0.5H₂O•0.1EtOH: C, 34.82; H, 4.18; N, 19.91.

Example 57: 1-Guanidino-7-phenylsulphamoylisoquinoline


Guanidine hydrochloride (100 mg, 1.05 mmol) was added in one portion to a suspension of sodium hydride (NaH) (30 mg, 80% dispersion by wt. in mineral oil, 1.0 mmol) in dimethylsulphoxide (DMSO) (3.5 mL) and the mixture was heated at 60 °C under nitrogen (N₂) for 30 minutes. 1-Chloro-7-phenylsulphamoylisoquinoline (110 mg, 0.345 mmol) was added and the mixture was heated at 100 °C for 3 d. The solvents were evaporated *in vacuo* and the residue was purified by column chromatography (silica gel using CH₂Cl₂-methanol-0.880NH₃ (97:3:0.3 to 90:10:1) as eluant) to give 1-guanidino-7-phenylsulphamoylisoquinoline (16 mg, 0.047 mmol) as an off-white solid. mp 186-188 °C.

¹H (DMSO-*d*₆, 400 MHz) δ 6.95 (2H, d), 7.05 (2H, d), 7.1-7.3 (4H, br s) 7.15-7.2 (2H, m), 7.7 (1H, d), 7.75 (1H, d), 8.0 (1H, d), 9.0 (1H, s), 10.2 (1H, s) ppm.

LRMS 341 (MH^+).

Found: C, 51.44; H, 4.14; N, 19.50. Calc for $C_{16}H_{15}N_5O_2S \cdot 0.1CH_2Cl_2 \cdot 1.2H_2O$: C, 52.05; H, 4.78; N, 18.85.

5 Example 58: (i) 4-Chloro-1-guanidino-7-sulphamoylisoquinoline



Guanidine hydrochloride (70 mg, 0.73 mmol) was added in one portion to a suspension of NaH (21 mg, 80% dispersion by wt in mineral oil, 0.66 mmol) in DMSO (2.0 mL) and the mixture was heated at 50 °C under N_2 for 30 min. 1,4-Dichloro-7-sulphamoylisoquinoline (70 mg, 0.25 mmol) was added and the mixture heated at 90 °C for 18 h. The cooled mixture was partitioned between ethyl acetate (EtOAc) and water, and the organic phase was washed with brine, dried ($MgSO_4$) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH_2Cl_2 -MeOH-0.880 NH_3 (95:5:0.5 to 90:10:1) as eluant to give 4-chloro-1-guanidino-7-sulphamoylisoquinoline (50 mg, 0.167 mmol) as a white solid.

mp 230 °C (dec).

1H (DMSO- d_6 , 300 MHz) δ 7.1-7.5 (4H, br s), 7.4 (2H, br s), 8.0 (1H, d), 8.1 (1H, s), 8.15 (1H, d), 9.1 (1H, s) ppm.

20 LRMS 300, 302 (MH^+), 599 (M_2H^+).

Found: C, 39.49; H, 3.37; N, 22.63. Calc for $C_{10}H_{10}ClN_5O_2S \cdot 0.25H_2O$: C, 39.48; H, 3.48; N, 23.02.

(ii) 4-Chloro-1-guanidino-7-sulphamoylisoquinoline hydrochloride

4-Chloro-1-guanidino-7-isoquinolinesulphonamide (30 mg, 0.10 mmol) was dissolved in a solution of EtOH saturated with HCl gas (2.0 mL) and the mixture stirred at room temperature for 1 h. The solvents were evaporated *in vacuo* and the residue was azeotroped with CH₂Cl₂ to give 4-chloro-1-guanidino-7-isoquinolinesulphonamide hydrochloride (32 mg, 0.095 mmol) as a white solid.


mp 296 °C (dec).

¹H (DMSO-*d*₆, 400 MHz) δ 7.6 (2H, s), 7.7 (1H, d), 8.2 (1H, s), 8.2 (1H, d), 8.3 (1H, d), 8.4-9.0 (4H, br s), 9.1 (1H, d), 11.0 (1H, s) ppm.

LRMS 300, 302 (MH⁺), 599 (M₂H⁺).

10 Found: C, 35.55; H, 3.26; N, 20.13. Calc for C₁₀H₁₀ClN₅O₂S•1.0HCl•0.05CH₂Cl₂: C, 35.46; H, 3.29; N, 20.57.

Example 59: 4-Chloro-7-cyclopentylsulphamoyl-1-guanidinoisoquinoline



15

The title compound was prepared by same the general method as Example 56.

mp >250 °C (dec).

¹H (DMSO-*d*₆, 400 MHz) δ 1.2-1.4 (4H, m), 1.4-1.6 (4H, m), 3.4 (1H, m), 7.7-7.8 (1H, br d), 8.0-8.2 (2H, m), 9.1 (1H, s) ppm.


20 LRMS 368 (MH⁺).

Found: C, 48.23; H, 4.97; N, 18.44. Calc for C₁₅H₁₈ClN₅O₂S•0.1CH₂Cl₂: C, 48.19; H, 4.87; N, 18.61.

Example 60: 4-Chloro-1-guanidino-7-(1-pyrrolidinosulphonyl)isoquinoline hydrochloride

25

44



The title salt was prepared by same the general method as Example 56.

mp 299-300 °C.


¹H (DMSO-*d*₆, 300 MHz) δ 1.6-1.7 (4H, m), 3.2-3.3 (4H, m), 8.2-8.9 (4H, br s), 8.3 (1H, d),

5 8.4 (1H, d), 8.5 (1H, s), 9.1 (1H, s) ppm..

LRMS 354 (MH⁺).

Found: C, 43.71; H, 4.69; N, 16.67. Calc for C₁₄H₁₆ClN₅O₂S•HCl•0.3EtOAc: C, 43.81; H, 4.69; N, 16.81.

10 Example 61: 4-Chloro-1-guanidino-7-morpholinosulphonylisoquinoline hydrochloride



The title salt was prepared by same the general method as Example 56.


15 mp 285 °C (dec).

¹H (Trifluoroacetic acid-*d*, 400 MHz) δ 3.4 (4H, s), 4.1 (4H, s), 8.3 (1H, d), 8.5 (1H, s), 8.65 (1H, d), 9.1 (1H, s) ppm.

LRMS 370,372 (MH⁺).

Found: C, 41.69; H, 4.32; N, 16.17. Calc for C₁₄H₁₆ClN₅O₃S•HCl•0.5MeOH: C, 41.24; H,

20 4.53; N, 16.58.

Example 62: 4-Chloro-1-guanidino-7-[(N-methylpiperazino)sulphonyl]isoquinoline


5 The title compound was prepared by same the general method as Example 56.

mp 262-263 °C (dec).

¹H (Trifluoroacetic acid-*d*, 400 MHz) δ 3.1 (3H, s), 3.3 (2H, m), 3.4 (2H, m), 3.9 (2H, m), 4.2 (2H, s), 8.3 (1H, d), 8.5 (1H, s), 8.7 (1H, d), 9.0 (1H, s) ppm.

10 LRMS 383, 385 (MH⁺).

Found: C, 46.70; H, 4.99; N, 21.62. Calc for C₁₅H₁₉ClN₆O₂S•0.25MeOH: C, 46.86; H, 5.16; N, 21.50.

Example 63: 4-Chloro-1-guanidino-7-(phenylsulphonyl)isoquinoline

15

NaH (13.6 mg, 80% dispersion by wt in mineral oil, 0.45 mmol) was added in one portion to a solution of guanidine hydrochloride (44 mg, 0.46 mmol) in DMSO (2 mL) and the mixture was heated at 80 °C under N₂ for 10 min. 1,4-Dichloro-7-(phenylsulphonyl)isoquinoline (60 mg, 0.195 mmol) was added and the mixture heated at 80 °C for 1 h. The cooled mixture was poured into water (20 mL) and extracted with EtOAc (3x15 mL). The combined organic

20


extracts were washed with brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was extracted with hexanes-*i*- Pr_2O and this organic solution was decanted, and then stirred with a solution of HCl in Et_2O to give a precipitate. The white solid was collected by filtration and dried *in vacuo* to give 4-chloro-1-guanidino-7-(phenylsulphonyl)isoquinoline (51 mg, 0.13 mmol).

^1H (DMSO- d_6 , 300 MHz) δ 7.3-7.5 (5H, m), 7.7 (1H, d), 8.1-9.2 (4H, br s), 8.1 (1H, d), 8.3 (1H, s), 9.0 (1H, s), 11.3 (1H, s) ppm.

LRMS 329 (MH^+).

Anal. Found: C, 50.54; H, 3.95; N, 14.81. Calc for $\text{C}_{16}\text{H}_{13}\text{ClN}_4\text{S}\cdot\text{HCl}\cdot 0.75\text{H}_2\text{O}$: C, 50.73; H, 4.12; N, 14.79.

Example 64: 4-Chloro-1-guanidino-7-(phenylsulphonyl)isoquinoline



NaH (18 mg, 80% dispersion by wt in mineral oil, 0.60 mmol) was added in one portion to a solution of guanidine hydrochloride (90 mg, 0.94 mmol) in DMSO (2 mL) and the mixture was heated at 50 °C under N_2 for 30 min. 1,4-Dichloro-7-(phenylsulfonyl)isoquinoline (80 mg, 0.236 mmol) was added and the mixture heated at 50-60 °C for 0.5 h. The cooled mixture was poured into water (30 mL) and extracted with EtOAc (3x20 mL). The combined organic extracts were washed with brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was dissolved in EtOAc and a solution of HCl in Et_2O (1 M) was added which gave a precipitate. The solvents were evaporated *in vacuo* and the residue triturated with EtOAc to give 4-chloro-1-guanidino-7-(phenylsulphonyl)isoquinoline (65 mg, 0.18 mmol) as a yellow solid.

¹H (DMSO-*d*₆, 400 MHz) δ 7.6-7.75 (3H, m), 8.1-9.2 (4H, br s), 8.2 (2H, d), 8.35 (1H, d), 8.4 (1H, d), 8.45 (1H, s), 9.5 (1H, s), 11.7 (1H, s) ppm.

LRMS 361 (MH⁺).

Anal. Found: C, 48.17; H, 3.75; N, 13.16. Calc for C₁₆H₁₃ClN₄O₂S•HCl•0.25H₂O•0.2EtOAc:

5 C, 48.11; H, 3.87; N, 13.36.

Preparation 1: 4,7-Dibromoisquinoline

Bromine (2.77 mL, 53.8 mmol) was added dropwise over 20 min. to a stirred suspension of a
10 1:1 mixture of 5- and 7-bromoisquinoline hydrochlorides (prepared by cyclisation of dimethyl(3-bromobenzylidene)aminoacetal according to the procedure of F. T. Tyson *J. Am. Chem. Soc.* **1939**, *61*, 183-5) (11.43 g, 48.2 mmol) in nitrobenzene (12.5 mL) and the mixture was heated at 170°C for 5 h. The mixture was cooled to 80°C, diluted with toluene (50 mL) which gave a precipitate and left at 23°C overnight. The mother liquors were decanted with
15 toluene rinsing (2x20 mL). The solid was digested in aqueous sodium hydroxide (100 mL, 1 M), extracted with ether (3x100 mL) and the ether phase was dried over magnesium sulphate (MgSO₄) and concentrated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (96:4 to 80:20) as eluant to give 4,7-dibromoisquinoline (5.91 g, 20.6 mmol) as a white solid.

20 M.Pt. 107-110°C;

¹H NMR (δ, CDCl₃, 300 MHz) 7.9 (1H, d), 8.05 (1H, d), 8.15 (1H, s), 8.75 (1H, s), 9.1 (1H, s);

LRMS 285, 287 (MH);

Elemental Analysis - Found: C, 37.90; H, 1.67; N, 4.83. Calculated for C₉H₅Br₂N: C, 37.67;

25 H, 1.76; N, 4.88.

Preparation 2 : 4-Bromo-7-phenylisoquinoline

A mixture of 4,7-dibromoisquinoline (556 mg, 1.93 mmol), tetrakis(triphenylphosphine)-
30 palladium(0) (73 mg, 3 mol%), phenylboronic acid (238 mg, 1.95 mmol), and aqueous

sodium carbonate (Na_2CO_3) (3.9 mL, 1.0 M, 3.9 mmol) in DME (12 mL) was heated at reflux under nitrogen for 20 h. The mixture was diluted with ethyl acetate (EtOAc) (100 mL), washed with water (30 mL), dried over MgSO_4 and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (95:5 to 80:20) as eluant to give 4-bromo-7-phenylisoquinoline (389 mg, 1.37 mmol) as a straw-colour solid; ^1H (8, CDCl_3 , 300 MHz) 7.4-7.6 (3H, m), 7.65-7.75 (2H, m), 8.1 (1H, d), 8.15 (1H, s), 8.2 (1H, d), 8.7 (1H, s), 9.2 (1H, s); LRMS 283, 284, 286.

Preparation 3 : 7-Bromo-1,4-dichloroisoquinoline

10

(i) A solution of 4-bromocinnamic acid (5.03 g, 22.2 mmol) in thionyl chloride (SOCl_2) (15 mL) was stirred at 23°C for 16 h, and then heated at reflux for a further 2 h. The solvents were evaporated *in vacuo* and the residue azeotroped with toluene (x3) to yield 4-bromocinnamoyl chloride as an orange-brown solid in quantitative yield.

15 ^1H NMR (δ , CDCl_3 , 300 MHz) 6.65 (1H, d), 7.4 (2H, d), 7.6 (2H, d), 7.8 (1H, d).

(ii) A solution of sodium azide (NaN_3) (2.2 g, 33.8 mmol) in water (7.5 mL) was added dropwise over 5 min to a stirred solution of 4-bromocinnamoyl chloride (22.2 mmol) in acetone (22 mL) at -10°C. The heterogeneous mixture was stirred at 0°C for 1 h and diluted with water (25 mL). The precipitate was collected by filtration and dried *in vacuo* over phosphorus pentoxide (P_2O_5) to give 4-bromocinnamoyl azide (5.22 g, 20.7 mmol) as a golden-coloured solid.

20 ^1H NMR (δ , CDCl_3 , 300 MHz) 6.4 (1H, d), 7.4 (2H, d), 7.5 (2H, d), 7.65 (1H, d).

25 (iii) [NB This stage is potentially explosive - take care and use a blast screen.]

A warm solution of 4-bromocinnamoyl azide (5.22 g, 20.7 mmol) in diphenyl ether (Ph_2O) (25 mL) was added dropwise over 15 min to stirred Ph_2O (10 mL) at 270°C. The mixture was heated at 270°C for 1.5 h, cooled to 23°C and then poured into hexanes (400 mL). The precipitate was collected by filtration with hexanes (2x100 mL) rinsing and purified by

column chromatography upon silica gel using hexanes-EtOAc (6:4 to 100 % EtOAc) as eluant to give 7-bromoisoquinolone (1.64 g, 7.3 mmol) as a white solid.

¹H NMR (δ, DMSO-*d*₆, 300 MHz) 6.55 (1H, d), 7.25-7.15 (1H, m), 7.6 (1H, d), 7.8 (1H, d), 8.25 (1H, s), 11.4 (1H, br s).

5

(iv) A mixture of 7-bromoisoquinolone (1.28 g, 5.69 mmol) and PCl₅ (2.04 g, 9.80 mmol) was heated at 140°C for 5 h. The cooled mixture was quenched with ice (50 g) and 0.880 ammonia was added until alkaline by litmus paper. The aqueous mixture was extracted with dichloromethane (3x50 mL) and the combined organic phases were dried over MgSO₄ and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (97:3 to 95:5) as eluant to give 7-bromo-1,4-dichloroisoquinoline (1.13 g, 4.08 mmol) as a white solid.

10

M.Pt. 133.5-135°C;

¹H (δ, CDCl₃, 300 MHz) 7.9 (1H, d), 8.1 (1H, d), 8.35 (1H, s), 8.5 (1H, s);

15 LRMS 276, 278 (MH);

Elemental Analysis - Found: C, 39.04; H, 1.32; N, 5.06. Calcd for C₉H₄BrCl₂N: C, 39.03; H, 1.46; N, 5.06.

Preparation 4 : 6-Bromoisoquinoline N-oxide

20

Acetic acid (8 mL) and 30 % hydrogen peroxide (4 mL) were heated at 80°C for 1 h. The cooled solution of peracetic acid was added to 6-bromoisoquinoline (Tyson, F.T. *J. Am. Chem. Soc.*, 1939, 61, 183) (0.389 g, 1.87 mmol) and the mixture was then heated at 80°C for 18 h. The mixture was diluted with water (15 mL) and concentrated *in vacuo* to ca. half the volume and the residue was extracted with CH₂Cl₂ (2x25 mL). The combined organics were washed with saturated aqueous NaHCO₃ (25 mL), dried over MgSO₄ and evaporated to leave an oil. Azeotroping with PhMe (x3) and then CH₂Cl₂ (x3) gave 6-bromoisoquinoline N-oxide (0.420 g, quant) as a cream-coloured solid. ¹H (δ, CDCl₃, 300 MHz) 7.6-7.65 (2H, m), 7.77 (1H, dd), 8.0 (1H, s), 8.2 (1H, dd), 8.85 (1H, s); LRMS 223, 226 (MH).

25

30

The following compounds of Preparations 5 to 8 were prepared in a similar manner:

Preparation 5 : (i) 5-Bromoisoquinoline N-oxide and (ii) 7-bromoisoquinoline N-oxide

- 5 The title compounds (1:1, mixture) were prepared from a 1:1 mixture of 5-bromoisoquinoline and 7-bromoisoquinoline, as a white powder.

M.Pt. 149-151°C;

¹H NMR (δ, CDCl₃, 300 MHz) 7.5 (1H, dd), 7.6-7.7 (4H, m), 7.85 (1H, d), 7.9 (1H, s), 8.05 (1H, d), 8.1 (1H, dd), 8.2 (1H, dd), 8.7 (1H, s), 8.75 (1H, s);

- 10 LRMS 224 (MH).

Preparation 6 : (i) 5-Cyanoisoquinoline N-oxide and (ii) 7-cyanoisoquinoline N-oxide

- 15 The title compounds (1:1, mixture) were prepared from a 1:1 mixture of 5-cyanoisoquinoline and 7-cyanoisoquinoline (Tyson, F.T. *J. Am. Chem. Soc.*, 1939, 61, 183), as a pale yellow powder.

¹H NMR (δ, DMSO-*d*₆, 300 MHz) 7.8 (1H, dd), 7.85 (1H, d), 7.95 (1H, d), 8.05 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 8.2 (1H, s), 8.25-8.35 (2H, m), 8.45 (1H, s), 9.0 (1H, s), 9.1 (1H, s);

LRMS 171 (MH), 341 (M₂H).

20

Preparation 7 : 4,7-Dibromoisoquinoline N-oxide

The title compound was prepared from 4,7-dibromoisoquinoline.

¹H (δ, DMSO-*d*₆, 300 MHz) 7.85 (1H, d), 7.9 (1H, d), 8.25 (1H, s), 8.65 (1H, s), 8.95 (1H, s);

- 25 LRMS 302, 303, 305, 306 (MH).

Preparation 8: 4-Bromo-7-phenylisoquinoline N-oxide

- 30 The title compound was prepared from 4-bromo-7-phenylisoquinoline as a lemon-coloured solid.

¹H NMR (δ, DMSO-*d*₆, 300 MHz) 7.4-7.6 (3H, d), 7.75-7.85 (2H, m), 8.05 (2H, s), 8.25 (1H, s), 8.6 (1H, s), 9.0 (1H, s);
LRMS 299, 301 (MH).

5 Preparation 9 : 7-Benzyloxyisoquinoline N-oxide

A solution of 7-benzyloxyisoquinoline (International Patent Application publication no. WO 94/20459) (0.50 g, 2.13 mmol) in CH₂Cl₂ (20 mL) was stirred with 3-chloroperbenzoic acid (mCPBA) (1.1 g, 3.19 mmol) at room temperature for 2.5 h. The mixture was diluted with
10 CH₂Cl₂, and then washed with sodium dithionite (1 M), potassium carbonate (1 M) and brine. The organic layer was dried over MgSO₄ and evaporated *in vacuo* to leave 7-benzyloxyisoquinoline N-oxide (0.521 g, 2.09 mmol) as a cream-coloured powder.
¹H (δ, CDCl₃, 400 MHz) 5.15 (2H, s), 7.25 (1H, d), 7.3-7.5 (5H, m), 7.55 (1H, d), 7.65 (1H, d), 8.0 (1H, d), 8.6 (1H, s);
15 LRMS 252 (MH).

The following compounds of Preparations 10-14 were prepared in a similar manner:

20 Preparation 10: 5-(Ethoxycarbonylmethoxy)isoquinoline N-oxide

The title compound was prepared from 5-(ethoxycarbonylmethoxy)isoquinoline (see British Patent application publication no. GB 2065121 A) as a tan-coloured solid.
¹H NMR (δ, CDCl₃, 400 MHz) 1.3 (3H, t), 4.2 (2H, q), 4.8 (2H, s), 6.8 (1H, d), 7.3 (1H, d), 7.4 (1H, dd), 8.05-8.15 (2H, m), 8.7 (1H, s);
25 LRMS 248 (MH).

Preparation 11: 5-Benzyloxyisoquinoline N-oxide

The title compound was prepared from 5-benzyloxyisoquinoline (see Japanese Patent
30 application JP 51070772) as a yellow solid.

^1H (δ , CDCl_3 , 400 MHz) 5.2 (2H, s), 6.95 (1H, d), 7.25 (1H, d), 7.3-7.5 (6H, m), 8.1 (2H, s), 8.7 (1H, s);
LRMS 252 (MH).

5 Preparation 12: 5-Phenylisoquinoline N-oxide

The title compound was prepared from 5-phenylisoquinoline (Pridgen, L.N. *J. Het. Chem.* 1980, 17, 1289) as a yellow viscous oil.

10 ^1H NMR (δ , $\text{DMSO}-d_6$, 400 MHz) 7.4-7.5 (6H, m), 7.6 (1H, d), 7.7 (1H, dd), 7.9 (1H, d), 8.1 (1H, d), 9.0 (1H, s);
LRMS 222 (MH).

Preparation 13: 6-Methylisoquinoline N-oxide

15 The title compound was prepared from 6-methylisoquinoline (Brown, E.V. *J. Org. Chem.* 1977, 42, 3208) as an off-white solid.

^1H (δ , $\text{DMSO}-d_6$, 300 MHz) 2.5 (3H, s), 7.5 (1H, d), 7.7 (1H, s), 7.75-7.85 (2H, m), 8.1 (1H, d), 8.85 (1H, s);
LRMS 160 (MH), 319 (M_2H).

20

Preparation 14: 6,7-(Methylenedioxy)isoquinoline N-oxide

The title compound was prepared from 6,7-(methylenedioxy)isoquinoline (P.Fritsch, *Ann.* 1895, 286, 1) as a cream-coloured solid.

25 ^1H (δ , $\text{DMSO}-d_6$, 400 MHz) 6.1 (2H, s), 7.05 (1H, s), 7.15 (1H, s), 7.7 (1H, d), 8.0 (1H, d), 8.7 (1H, s);
LRMS 190 (MH), 379 (M_2H).

Preparation 15 : 6-Bromo-1-chloroisoquinoline

30

Phosphorus oxychloride (0.60 mL, 6.44 mmol) was added in one portion to a stirred solution of 6-bromoisoquinoline *N*-oxide (409 mg, 1.83 mmol) in CH₂Cl₂ (10 mL) and the mixture was heated at reflux for 6 hours. Excess solvents were evaporated *in vacuo*, the residue suspended in water (10 mL) and basified with 0.880 ammonia. This mixture was extracted with CH₂Cl₂ (2x25 mL) and the combined organics were dried over MgSO₄ and evaporated *in vacuo* to leave the crude product. Purification by column chromatography upon silica gel using hexanes-EtOAc (90:10) as eluant gave 6-bromo-1-chloroisoquinoline (215 mg, 0.86 mmol) as a cream-coloured solid.

M.Pt. 105-107°C;

¹H (δ, CDCl₃, 300 MHz) 7.5 (1H, d), 7.75 (1H, dd), 8.05 (1H, d), 8.2 (1H, d), 8.3 (1H, d);

LRMS 244 (MH);

Elemental Analysis - Found: C, 44.50; H, 1.98; N, 5.73. Calcd for C₉H₅BrClN: C, 44.58; H, 2.08; N, 5.78.

The compounds of Preparations 16-25 listed below were prepared similarly from the corresponding *N*-oxides from Preparation 15:

Preparation 16: 1-Chloro-5-(ethoxycarbonylmethoxy)isoquinoline

The title compound was prepared from 5-(ethoxycarbonylmethoxy)isoquinoline *N*-oxide as a white solid.

M.Pt. 52-4°C;

¹H NMR (δ, CDCl₃, 300 MHz) 1.3 (3H, t), 4.3 (2H, q), 4.8 (2H, s), 7.0 (1H, d), 7.65 (1H, dd), 7.9 (1H, d), 8.1 (1H, d), 8.3 (1H, d);

LRMS 265 (MH);

Elemental Analysis - Found: C, 58.70; H, 4.48; N, 5.18. Calcd for C₁₃H₁₂ClNO₃: C, 58.77; H, 4.48; N, 5.18.

Preparation 17 : 5-Benzoyloxy-1-chloroisoquinoline

The title compound was prepared from 5-benzyloxyisoquinoline N-oxide as a white solid.

M.Pt. 95-96°C;

¹H (δ, CDCl₃, 300 MHz) 5.2 (2 H,s), 7.1 (1H, d), 7.3-7.5 (5H, m), 7.55 (1H, dd), 7.85 (1H, d), 8.0 (1H, d), 8.2 (1H, d);

5 LRMS 270,272 (MH);

Elemental Analysis - Found: C, 71.18; H, 4.43; N, 5.09. Calcd for C₁₆H₁₂ClNO: C, 71.25; H, 4.48; N, 5.19.

Preparation 18 : 1-Chloro-5-phenylisoquinoline

10

The title compound was prepared from 5-phenylisoquinoline N-oxide as an oil.

¹H NMR (CDCl₃, 400 MHz) 7.35-7.55 (5H, m), 7.6-7.75 (3H, m), 8.2 (1H, d), 8.35 (1H, d);

LRMS 240, 242 (MH);

El.Anal. Found: C, 74.66; H, 4.17; N, 5.81. Calcd for C₁₅H₁₀ClN + 0.1 H₂O: C,74.66; H,

15 4.26; N, 5.80.

Preparation 19: 1-Chloro-6-methylisoquinoline

20 The title compound was prepared from 6-methylisoquinoline N-oxide, as a straw-coloured solid.

¹H NMR (δ, CDCl₃, 300 MHz) 2.6 (3H, s), 7.45-7.6 (2H, m), 7.6 (1H, s), 8.2-8.3 (2H, m);

LRMS 178, 180 (MH).

Preparation 20: 7-Bromo-1-chloroisoquinoline

25

The title compound was prepared from a mixture of 5- and 7-bromoisoquinoline N-oxides and separated from 5-bromo-1-chloroisoquinoline by chromatography, to give a white solid.

¹H (δ, CDCl₃, 300 MHz) 7.5 (1H, d), 7.7 (1H, d), 7.8 (1H, d), 8.3 (1H, d), 8.5 (1H, s);

LRMS 244, 246 (MH).

30

Preparation 21: 1-Chloro-7-cyanoisoquinoline

The title compound was prepared from a mixture of 5- and 7-cyanoisoquinoline N-oxides and separated from 1-chloro-5-cyanoisoquinoline by chromatography, to give a white powder.

- 5 ^1H (δ , CDCl_3 , 400 MHz) 7.7 (1H, d), 7.9 (1H, d), 7.95 (1H, d), 8.45 (1H, d), 8.75 (1H, s);
LRMS 189 (MH).

Preparation 22: 7-Benzyloxy-1-chloroisoquinoline

- 10 The title compound was prepared from 7-benzylisoquinoline N-oxide, giving a white powder.
M.Pt. 128-31°C;

^1H (δ , CDCl_3 , 400 MHz) 5.2 (2H, s), 7.3-7.5 (7H, m), 7.65 (1H, s), 7.75 (1H, d), 8.35 (1H, d);
LRMS 270, 272 (MH);

- El.Anal. Found: C, 71.04; H, 4.47; N, 5.12. Calcd for $\text{C}_{16}\text{H}_{12}\text{ClNO}$: C, 71.25; H, 4.48; N,
15 5.19.

Preparation 23: 1-Chloro-4,7-dibromoisoquinoline

The title compound was prepared from 4,7-dibromoisoquinoline N-oxide as a white solid.

- 20 ^1H (δ , CDCl_3 , 400 MHz) 7.9 (1H, dd), 8.05 (1H, d), 8.45 (1H, s), 8.5 (1H, d);
LRMS 321 (MH).

Preparation 24: 4-Bromo-1-chloro-7-phenylisoquinoline

- 25 The title compound was prepared from 4-bromo-7-phenylisoquinoline N-oxide as a white solid.

M.Pt. 144-7°C;

^1H (δ , CDCl_3 , 300 MHz) 7.4-7.6 (3H, m), 7.7-7.75 (2H, m), 8.1 (1H, d), 8.25 (1H, d), 8.45
(1H, s), 8.5 (1H, s);

- 30 LRMS 321 (MH);

El. Anal. Found: C, 56.71; H, 2.89; N, 4.30. Calcd for $C_{15}H_9BrClN$: C, 56.55; H, 2.85; N, 4.40.

Preparation 25: 1-Chloro-6,7-(methylenedioxy)isoquinoline

5

The title compound was prepared from 6,7-(methylenedioxy)isoquinoline N-oxide as a cream solid.

1H NMR (δ , $CDCl_3$, 300 MHz) 6.15 (2H, s), 7.05 (1H, s), 7.4 (1H, d), 7.6 (1H, s), 8.1 (1H, d); LRMS 207, 210 (MH).

10

Preparation 26 : 3,5-dimethoxyphenylboronic acid

15

To 1-bromo-3,5-dimethoxybenzene (1.4 g, 6.45 mmol) (Dean, N.B; Whalley, W.B. *J. Chem. Soc.* 1954, 4638) in THF (60 mL) under nitrogen at $-70^\circ C$ was added *n*-BuLi (2.6 mL, 2.5M in hexanes). After 10 min. the clear yellow solution was treated with trimethyl borate (1.5 mL, 13.2 mmol) in THF (2 mL) and stirred for a further hour, allowed to warm to room temperature over 3 hours and quenched with water (10 mL). After dilution with water (50 mL) the mixture was extracted with methylene chloride (x2). The combined organics were washed with brine and concentrated to an off-white solid which was recrystallised from diethyl ether to give a white solid (400 mg, 2.2 mmol).

20

M.Pt. $195-7^\circ C$;

1H NMR (δ , $DMSO-d_6$, 400 MHz) 3.7 (3H, s), 3.75 (3H, s), 6.45-6.5 (1H, m), 6.85-6.95 (2H, m);

LRMS 183 (MH).

25

Preparation 27 : 1,4-Dichloro-7-(4-methylphenyl)isoquinoline

30

A mixture of 7-bromo-1,4-dichloroisoquinoline (276 mg, 1.0 mmol), tetrakis-(triphenylphosphine)palladium(0) (60 mg, 5 mol%), 4-methylphenylboronic acid (137 mg, 1.00 mmol), and aqueous Na_2CO_3 (2.0 mL, 1.0 M, 2.0 mmol) in DME (6 mL) was heated at

reflux under N₂ for 20 h. The mixture was diluted with EtOAc (100 mL), washed with water (30 mL), dried over MgSO₄ and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (99:1 to 97:3) as eluant to give 1,4-dichloro-7-(4-methylphenyl)isoquinoline (139 mg, 0.48 mmol) as a solid.

- 5 ¹H (δ, CDCl₃, 300 MHz) 2.45 (3H, s), 7.35 (2H, d), 7.65 (2H, d), 8.1 (1H, dd), 8.25 (1H, d), 8.3 (1H, s), 8.5 (1H, d);
LRMS 288, 290, 292 (MH).

The following compounds of Preparations 28-41 were prepared similarly:

10

Preparation 28 : 1-Chloro-7-phenylisoquinoline

The title compound was prepared from 7-bromo-1-chloroisoquinoline and phenylboronic acid, as an oil.

- 15 ¹H (δ, CDCl₃, 400 MHz) 7.4-7.55 (3H, m), 7.65 (1H, d), 7.75 (2H, d), 7.9 (1H, d), 8.05 (1H, d), 8.3 (1H, d), 8.55 (1H, s);
LRMS 240 (MH).

Preparation 29 : 1-Chloro-7-(3,4-methylenedioxyphenyl)isoquinoline

20

The title compound was prepared from 7-bromo-1-chloroisoquinoline and 3,4-methylenedioxyphenylboronic acid (Banwell, M.G.; Cowden, C.J. *Aust. J. Chem.* 1994, 47, 2235), as a white powder.

- 25 ¹H (δ, CDCl₃, 400 MHz) 6.1 (2H, s), 7.05 (1H, d), 7.3 (1H, d), 7.4 (1H, s), 7.9 (1H, d), 8.1 (1H, d), 8.15 (1H, d), 8.25 (1H, d), 8.3 (1H, s);
LRMS 284, 286 (MH);

El.Anal. Found: C, 67.54; H, 3.51; N, 4.87. Calcd for C₁₆H₁₀ClNO₂: C, 67.74; H, 3.55; N, 4.94.

- 30 Preparation 30: 7-(2-Benzofuranyl)-1,4-dichloroisoquinoline

The title compound was prepared from 7-bromo-1,4-dichloroisoquinoline and benzo[b]furan-2-boronic acid as a yellow solid.

M.Pt. 162°C;

5 ^1H (δ , CDCl_3 , 400 MHz) 7.25-7.3 (2H, m), 7.3 (1H, dd), 7.55-7.65 (2H, m), 8.25 (2H, d), 8.3 (1H, d), 8.75 (1H, s);

LRMS 316 (MH);

El.Anal. Found: C, 62.93; H, 2.79; N, 4.33. Calcd for $\text{C}_{17}\text{H}_9\text{Cl}_2\text{NO}$: C, 63.21; H, 2.97; N, 4.32.

10

Preparation 31: 1,4-Dichloro-7-(3-thienyl)isoquinoline

The title compound was prepared from 7-bromo-1,4-dichloroisoquinoline and thiophene-3-boronic acid, as a yellow solid.

15 M.Pt. 109°C;

^1H (δ , CDCl_3 , 400 MHz) 7.45 (1H, d), 7.5 (1H, d), 7.7 (1H, s), 8.1 (1H, d), 8.2 (1H, d), 8.3 (1H, s), 8.45 (1H, s);

LRMS 280, 282 (MH).

20 Preparation 32: 1,4-Dichloro-7-(2-methoxyphenyl)isoquinoline

The title compound was prepared from 7-bromo-1,4-dichloroisoquinoline and 2-methoxyphenylboronic acid as a pale cream solid.

25 ^1H (δ , CDCl_3 , 400 MHz) 3.8 (3H, s), 7.05 (1H, d), 7.1 (1H, dd), 7.35-7.45 (2H, m), 8.05 (1H, d), 8.2 (1H, d), 8.3 (1H, s), 8.4 (1H, s);

LRMS 304, 306 (MH).

Preparation 33: 1,4-Dichloro-7-(3-methoxyphenyl)isoquinoline

The title compound was prepared from 7-bromo-1,4-dichloroisoquinoline and 3-methoxyphenylboronic acid as a pale cream solid.

^1H (δ , CDCl_3 , 300 MHz) 3.95 (3H, s), 7.0 (1H, d), 7.25 (1H, s), 7.3 (1H, d), 7.45 (1H, dd), 8.1 (1H, dd), 8.25 (1H, d), 8.35 (1H, s), 8.5 (1H, s);

5 LRMS 304, 306, 308 (MH).

Preparation 34: 1,4-Dichloro-7-(4-methoxyphenyl)isoquinoline

10 The title compound was prepared from 7-bromo-1,4-dichloroisoquinoline and 4-methoxyphenylboronic acid as a pale yellow solid.

M.Pt. 124-6°C;

^1H (δ , CDCl_3 , 400 MHz) 3.9 (3H, s), 7.05 (2H, d), 7.7 (2H, d), 8.1 (1H, d), 8.25 (1H, d), 8.3 (1H, s), 8.45 (1H, s);

LRMS 304, 306, 308 (MH);

15 El.Anal. Found: C, 62.28; H, 3.56; N, 4.46. Calcd for $\text{C}_{16}\text{H}_{11}\text{Cl}_2\text{NO} + 0.05 \text{CH}_2\text{Cl}_2$: C, 62.50; H, 3.63; N, 4.54.

Preparation 35: 1,4-Dichloro-7-(3,4-methylenedioxyphenyl)isoquinoline

20 The title compound was prepared from 7-bromo-1,4-dichloroisoquinoline and 3,4-methylenedioxyphenylboronic acid as a solid.

^1H (δ , $\text{DMSO}-d_6$, 300 MHz) 6.1 (2H, s), 7.1 (1H, d), 7.35 (1H, d), 7.45 (1H, s), 8.25 (1H, d), 8.35 (1H, d), 8.4 (1H, s), 8.45 (1H, s);

LRMS 318, 320 (MH).

25

Preparation 36 : 1,4-Dichloro-7-(3,5-dimethoxyphenyl)isoquinoline

The title compound was prepared from 7-bromo-1,4-dichloroisoquinoline and 3,5-dimethoxyphenylboronic acid as an off-white solid.

M.Pt. 140-2°C; ¹H (δ, CDCl₃, 400 MHz) 3.85 (6H, s), 6.55 (1H, s), 6.8 (2H, s), 8.1 (1H, d), 8.25 (1H, d), 8.3 (1H, s), 8.5 (1H, s);

LRMS 333, 335, 337 (MH);

El.Anal. Found: C, 61.17; H, 4.05; N, 3.78. Calcd for C₁₇H₁₃Cl₂NO₂ + 0.14 EtOAc: C, 60.86;

5 H, 4.11; N, 4.04.

Preparation 37 : 7-(3-Cyanophenyl)-1,4-dichloroisoquinoline

10 The title compound was prepared in a similar manner to Preparation 42, from 7-bromo-1,4-dichloroisoquinoline and 3-cyanophenylboronic acid (International Patent Application publication no. WO94/11372) to give a white solid.

M.Pt. 197-199°C;

¹H NMR (δ, CDCl₃, 300MHz) 8.5 (1H,s), 8.4 (1H,s), 8.3 (1H,d), 8.1 (1H,d), 8.0 (1H,s), 7.95 (1H,d), 7.7 (1H,d), 7.65 (1H,d);

15 LRMS 298,300;

El.Anal. Found C, 64.01; H, 2.67; N, 9.20. Calcd for C₁₆H₈Cl₂N₂ : C, 64.24; H, 2.70; N, 9.36.

Preparation 38 : 4-Bromo-1-chloro-7-(3-chlorophenyl)isoquinoline

20 The title compound was prepared in a similar manner to Preparation 42, from 1-chloro-4,7-dibromoisoquinoline and 3-chlorophenylboronic acid as a white solid.

M.Pt. 140-2°C;

¹H (δ, CDCl₃, 300 MHz) 7.4-7.55 (2H, m), 7.6 (1H, d), 7.75 (1H, s), 8.1 (1H, d), 8.3 (1H, d), 8.5 (2H, s);

25 LRMS 352, 354, 356 (MH);

El.Anal. Found: C, 50.38; H, 2.20; N, 3.93. Calcd for C₁₅H₈BrCl₂N: C, 50.60; H, 2.33; N, 3.93.

Preparation 39: 4-Bromo-1-chloro-7-(4-methylphenyl)isoquinoline

30

The title compound was prepared in a similar manner to Preparation 42, from 1-chloro-4,7-dibromoisquinoline and 4-methylphenylboronic acid as a solid.

M.Pt. 108-110°C;

¹H (δ, CDCl₃, 400 MHz) 2.4 (3H, s), 7.3 (2H, d), 7.6 (2H, d), 8.1 (1H, d), 8.2 (1H, d), 8.4 (1H, s), 8.45 (1H, s);

LRMS 332, 334, 336 (MH).

Preparation 40 : 4-Bromo-1-chloro-7-(4-methoxyphenyl)isoquinoline

10 The title compound was prepared in a similar manner to Preparation 42, from 1-chloro-4,7-dibromoisquinoline and 4-methoxyphenylboronic acid as a white solid.

M.Pt. 94-96°C;

¹H (δ, CDCl₃, 400 MHz) 3.85 (3H, s), 7.0 (2H, d), 7.65 (2H, d), 8.05 (1H, d), 8.15 (1H, d), 8.4 (2H, s);

15 LRMS 348, 350, 352 (MH);

El.Anal. Found: C, 55.16; H, 3.13; N, 4.02. Calcd for C₁₆H₁₁BrClNO: C, 55.12; H, 3.18; N, 4.02.

Preparation 41: 4-Bromo-1-chloro-7-(3-methoxyphenyl)isoquinoline

20

The title compound was prepared in a similar manner to Preparation 42, from 1-chloro-4,7-dibromoisquinoline and 3-methoxyphenylboronic acid as a white solid.

¹H (δ, CDCl₃, 400 MHz) 3.9 (3H, s), 6.9-7.05 (2H, m), 7.3 (1H, d), 7.4 (1H, d), 8.1 (1H, d), 8.2 (1H, d), 8.45 (1H, s), 8.5 (1H, s);

25 LRMS 347, 349, 351 (MH);

El.Anal. Found: C, 55.49; H, 3.20; N, 3.94. Calcd for C₁₆H₁₁BrClNO: C, 55.12; H, 3.18; N, 4.02.

Preparation 42: 1,4-Dichloro-7-(2,6-dimethoxyphenyl)isoquinoline

30

A solution of 7-bromo-1,4-dichloroisoquinoline (396 mg, 1.42 mmol) and 2,6-dimethoxyphenylboronic acid (261 mg, 1.43 mmol) (J.Chem.Soc., Chem. Commun. 1995, 1085) in anhydrous DME (10 mL) was treated with tetrakis(triphenylphosphine)palladium(0) (38 mg, 19 mol%) and caesium fluoride (485mg, 3.19mmol) and the resultant mixture heated at reflux under N₂ for 16 h. The reaction mixture was cooled to room temperature, partitioned between EtOAc (35 mL) and water (10 mL), dried and evaporated to give a solid which was purified by column chromatography upon silica gel using hexanes-EtOAc (99:1 to 96:4) as eluant to give the title compound as an off-white solid (120.6 mg, 0.36 mmol).

¹H (δ, CDCl₃, 300 MHz) 8.35 (1H, s), 8.3 (1H, s), 8.2 (1H, d), 7.85 (1H, d), 7.35 (1H, t), 6.7 (2H, d), 3.75 (6H, s);

LRMS 334, 336, 338 (MH).

Preparation 43 : 1-Chloro-7-(2-phenyl-*E*-ethenyl)isoquinoline

A solution of 7-bromo-1-chloroisoquinoline (200 mg, 0.80 mmol), styrene (94 mg, 0.90 mmol), tri-*o*-tolylphosphine (30 mg, 12 mol%), palladium (II) acetate (Pd(OAc)₂) (10 mg, 5 mol%) and triethylamine (0.34 mL, 2.5 mmol) in DMF (0.75 mL) were placed in a MOS-2000TM (650 W) microwave and irradiated at full power for 7x40s (reaction monitored by TLC). The mixture was poured into water and extracted with EtOAc. The combined organic layers were dried over MgSO₄, evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using hexanes-EtOAc (100:0 to 95:5) as eluant to give 1-chloro-(2-phenylethen-1-yl)isoquinoline (135 mg, 0.508 mmol) as a yellow solid.

M.Pt. 118-121°C ;

¹H (δ, CDCl₃, 300 MHz) 7.3-7.35 (3H, m), 7.44 (2H, dd), 7.55-7.65 (3H, m), 7.8 (1H, d), 8.0 (1H, d), 8.25 (1H, d), 8.3 (1H, s);

LRMS 266, 268 (MH);

El.Anal. Found: C, 76.87; H, 4.61; N, 5.18. Calcd for C₁₇H₁₂ClN: C, 76.84; H, 4.55; N, 5.27.

Preparation 44 : 1-chloro-5-isoquinolinecarboxaldehyde.

A solution of *n*-BuLi (1.76 mL, 2.5 M in hexanes, 4.4 mmol) was added to a stirred solution of 5-bromo-1-chloroisoquinoline (Braye, E.; Eloy, F.; Hoogzand, C.; Lenaers, R. *Eur. J. Med. Chem., Chim. Therap.* 1974, 9, 197) (1.0 g, 4.12 mmol) in THF-ether (36 mL, 1:1) at -78°C under N₂. After 20 minutes, DMF (0.66 mL, 8.5 mmol) was added and after an additional 30 minutes at -78°C the reaction was quenched with EtOH (3 mL) and warmed to room temperature. The mixture was diluted with ether (150 mL), washed with saturated NH₄Cl (50 mL), brine, dried over MgSO₄, and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (95:5 to 50:50) as eluant to give 1-chloro-5-isoquinolinecarboxaldehyde (308 mg, 1.61 mmol) as a white solid.

¹H (δ, CDCl₃, 400 MHz) 7.9 (1H, dd), 8.25 (1H, d), 8.5 (1H, d), 8.7 (1H, d), 9.0 (1H, d), 10.4 (1H, s);

LRMS 192, 194 (MH).

Preparation 45 : 1-chloro-7-isoquinolinecarboxaldehyde

The title compound was prepared in a similar manner to Prep.44, from 7-bromo-1-chloroisoquinoline, as a white solid.

¹H (δ, DMSO-*d*₆, 300 MHz) 7.95 (1H, d), 8.2 (2H, s), 8.4 (1H, d), 8.85 (1H, s), 10.2 (1H, s).

LRMS 192, 194 (MH).

Preparation 46 : 7-Carboxy-1-chloroisoquinoline hydrochloride

A solution of *n*-BuLi (1.2 mL, 2.5 M in hexanes, 3.0 mmol) was added dropwise to a stirred solution of the 7-bromo-1-chloroisoquinoline (0.64 g, 2.64 mmol) in THF (10 mL) and ether (10 mL) at -78°C under N₂. After 20 min, crushed solid CO₂ (excess) was added in one portion and the mixture allowed to warm to room temperature. The solvents were evaporated *in vacuo* and the residue partitioned between aqueous NaOH (20 mL, 0.5 M) and ether (50 mL). The aqueous phase was acidified with conc HCl, extracted with EtOAc (3x50 mL) and the combined organic extracts were dried over MgSO₄ and evaporated to leave 7-carboxy-1-chloroisoquinoline hydrochloride (0.277 g, 1.13 mmol) as an off-white solid.

^1H (δ , DMSO- d_6 , 300 MHz) 7.95 (1H, d), 8.15 (1H, d), 8.3 (1H, d), 8.4 (1H, d), 8.8 (1H, s), 13.5 (1H, br s);
LRMS 208, 210 (MH).

5 Preparation 47 : 1-Chloro-7-(1-hydroxycyclohex-1-yl)isoquinoline

A solution of 7-bromo-1-chloroisoquinoline (200 mg, 0.82 mmol) in anhydrous THF (4 mL) at -78°C was treated with *s*-BuLi (1.3M in cyclohexane, 0.7 mL, 0.91 mmol) to afford a dark green solution which after 4 minutes was quenched with cyclohexanone (100 mL, 0.96
10 mmol). The cooling bath was removed and the reaction mixture allowed to reach ambient temperature, stirred for 20 minutes and quenched with a drop of water. The THF was removed *in vacuo* and water (5 mL) added to the residue which was extracted with ethylacetate (3 x 10 mL). The combined organic extracts were washed with water (5 mL) and brine (5 mL) and then dried over MgSO_4 and condensed onto silica gel (1 g) and purified by
15 column chromatography (silica gel, 15 g) using hexanes-EtOAc (100:15 to 100:20) as eluant to afford the title compound as a white solid (83 mg, 0.32 mmol).

M.Pt. $109.5\text{--}111^\circ\text{C}$;

^1H (δ , CDCl_3 , 300 MHz) 1.3-2.1 (11H, m), 7.55 (1H, d), 7.85 (1H, d), 7.95 (1H, d), 8.25 (1H, d), 8.45 (1H, s);
20 LRMS 262, 264 (MH).

The following compounds of Preparations 48-51 were made in a similar manner:

Preparation 48 : 1-Chloro-7-(1-hydroxycyclopent-1-yl)isoquinoline

25

The title compound was prepared from 7-bromo-1-chloroisoquinoline quenching the formed anion with cyclopentanone to give a yellow solid.

^1H (δ , CDCl_3 , 300 MHz) 1.5-2.2 (9H, m), 7.6 (1H, d), 7.8 (1H, d), 7.9 (1H, d), 8.25 (1H, d), 8.45 (1H, s);
30 LRMS 248, 250 (MH).

Preparation 49 : 1-Chloro-7-(1-hydroxy-1-phenylethyl)isoquinoline

The title compound was prepared from 7-bromo-1-chloroisoquinoline quenching the formed
5 anion with acetophenone to give a cream solid.

M.Pt. 134-5°C;

¹H (δ, CDCl₃, 400 MHz) 2.0 (3H, m), 2.3 (1H, br s), 7.2-7.35 (3H, m), 7.35-7.45 (2H, m), 7.5
(1H, d), 7.65 (1H, d), 7.7 (1H, d), 8.2 (1H, d), 8.45 (1H, s);

LRMS 284, 286 (MH);

10 El.Anal. found: C, 71.49; H, 5.06; N, 4.90. Calcd for C₁₇H₁₄ClNO + 0.08 EtOAc: C, 71.54;
H, 5.07; N, 4.82.

Preparation 50 : 1-Chloro-7-(α-hydroxybenzyl)isoquinoline

15 The title compound was prepared from 7-bromo-1-chloroisoquinoline quenching the formed
anion with benzaldehyde to give a white solid.

¹H (δ, CDCl₃, 300 MHz) 2.45 (1H, d), 6.05 (1H, d), 7.2-7.45 (5H, m), 7.55 (1H, d), 7.7 (1H,
d), 7.75 (1H, d), 8.15 (1H, d), 8.4 (1H, s);

LRMS 270, 272 (MH);

20 El.Anal. Found: C, 70.11; H, 4.63; N, 4.85. Calcd for C₁₆H₁₂ClN + 0.2 EtOAc: C, 70.22; H,
4.77; N, 4.87.

Preparation 51 : 1,4-Dichloro-7-(α-hydroxybenzyl)isoquinoline

25 The title compound was prepared from 7-bromo-1,4-dichloroisoquinoline quenching the
formed anion with benzaldehyde to give a white solid.

M.Pt. 121-122°C;

¹H (δ, CDCl₃, 300 MHz) 2.3-2.6 (1H, br s), 6.1 (1H, s), 7.25-7.5 (5H, m), 7.85 (1H, d), 8.15
(1H, d), 8.3 (1H, s), 8.45 (1H, s);

30 LRMS 304, 306 (MH);

El. Anal. Found: C, 62.55; H, 3.45; N, 4.61. Calcd for $C_{16}H_{11}Cl_2NO + 0.2$ water: C, 62.44; H, 3.73; N, 4.55.

Preparation 52: 1-Chloro-7-(1-hydroxyethyl)isoquinoline

5

A slurry of 1-chloro-7-isoquinolinecarboxaldehyde (148 mg, 0.78 mmol) in anhydrous THF (8 mL) at -78°C was treated with MeLi (1.0M in THF, 0.86 mL, 0.86 mmol) over 30 min. After 15 min, the solution was warmed to 0°C and stirred for a further 1 h. The reaction mixture was then diluted with EtOAc (30 mL), washed with saturated ammonium chloride solution (20 mL), brine (20 mL), dried over MgSO_4 and condensed to an orange/brown oil. Purification by column chromatography upon silica gel (25 g) using hexanes-EtOAc (10:3) as eluant gave the title compound as a whitish oil (85 mg, 0.41 mmol).

10

^1H (δ , CDCl_3 , 400 MHz) 1.55 (3H, d), 2.15 (1H, s), 5.1 (1H, q), 7.55 (1H, d), 7.7-7.8 (2H, m), 8.2 (1H, d), 8.25 (1H, d);

15

LRMS 208, 210 (MH).

Preparation 53 : 1-Chloro-5-hydroxymethylisoquinoline

A solution of 1-chloro-5-isoquinolinecarboxaldehyde (308 mg, 1.6 mmol) and sodium borohydride (NaBH_4) (68 mg, 1.8 mmol) in MeOH (6 mL) was stirred at room temperature for 2 h. The reaction was quenched with water (2 mL) and concentrated *in vacuo*. The residue was suspended in CH_2Cl_2 , washed with water, with brine and then dried over MgSO_4 and evaporated. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (80:20 to 50:50) as eluant to give 1-chloro-5-(hydroxymethyl)isoquinoline (240 mg, 1.23 mmol) as a white solid.

20

25

^1H (δ , CDCl_3 , 400 MHz) 2.0 (1H, br s), 5.15 (2H, s), 7.7 (1H, dd), 7.8 (1H, d), 7.9 (1H, d), 8.35 (2H, m);

LRMS 193 (MH), 387 (M_2H).

30

Preparation 54: 1-Chloro-7-hydroxymethylisoquinoline

The title compound was prepared in a similar manner to Preparation 53, from 1-chloroisoquinoline-7-carboxaldehyde, to give a white powder.

M.Pt. 118-121°C;

5 ^1H (δ , DMSO- d_6 , 300 MHz) 4.7 (2H, d), 5.5 (1H, t), 7.8 (1H, d), 7.85 (1H, d), 8.0 (1H, d), 8.2 (1H, s), 8.25 (1H, d);

LRMS 194, 196 (MH);

El.Anal. Found: C, 62.24; H, 4.34; N, 7.01. Calcd for $\text{C}_{10}\text{H}_8\text{ClNO}$: C, 62.01; H, 4.16; N, 7.23.

10 Preparation 55 : 1-Chloro-7-chloromethylisoquinoline hydrochloride

1-Chloro-7-(hydroxymethyl)-isoquinoline (510 mg, 2.63 mmol) was slowly added to thionyl chloride (4 mL) at ambient temperature and the resultant mixture stirred for 1.5 h giving complete solution. The thionyl chloride was removed *in vacuo* and methylene chloride (20 mL) was added. The resultant white precipitate was removed by filtration and washed with further methylene chloride (20 mL) then dried *in vacuo* to afford the title compound (400 mg, 1.61 mmol). A second crop (112 mg, 0.45 mmol) was obtained by evaporation of the methylene chloride and trituration with ether/methylene chloride.

M.Pt. 138-140°C;

20 ^1H (δ , DMSO- d_6 , 300 MHz) 5.0 (2H, s), 7.8-7.95 (2H, m), 8.05 (1H, d), 8.25-8.35 (2H, m);
Elemental Analysis - Found: C, 47.98; H, 3.17; N, 5.58. Calcd for $\text{C}_{10}\text{H}_8\text{Cl}_3\text{N}$: C, 48.32; H, 3.24; N, 5.64.

Preparation 56 : 1-Chloro-7-[(2-methyl-1H-imidazol-1-yl)methyl]isoquinoline

25

Sodium hydride (60% dispersion in oil, 48 mg, 1.2 mmol) was added to a solution of 2-methylimidazole (100 mg, 1.2 mmol) in dry DMF (2 mL) and stirred at room temperature until evolution of H_2 had ceased after which the hydrochloride salt of 1-chloro-7-(chloromethyl)-isoquinoline (150 mg, 0.6 mmol) was added. The reaction mixture was stirred
30 for 3 h, poured into water (10 mL) and extracted with EtOAc (3x10 mL). The organic extracts

were combined, dried over MgSO_4 and condensed to an oil which was taken up in diisopropyl ether and allowed to crystallise. The solid was removed by filtration to afford white crystals of the title compound (70 mg, 0.27 mmol). A further crop of product (70 mg, 0.27 mmol) was obtained by concentration of the mother liquors.

5 ^1H (δ , CDCl_3 , 400 MHz) 2.35 (3H, s), 5.2 (2H, s), 6.85 (1H, s), 7.95 (1H, s), 7.35 (1H, d), 7.55 (1H, d), 7.8 (1H, d), 8.0 (1H, s), 8.15 (1H, d);

LRMS 258, 260 (MH);

El.Anal. Found: C, 65.14; H, 4.66; N, 16.28. Calcd for $\text{C}_{14}\text{H}_{12}\text{ClN}_3$: C, 65.24; H, 4.69; N, 16.31.

10

The compounds of Preparations 57 and 58 were made in a similar manner:

Preparation 57 : 1-Chloro-7-[(2-methyl-1*H*-benzo[d]imidazol-1-yl)methyl] isoquinoline

15 The title compound was prepared from 2-methylbenzimidazole to give a cream solid.

M.Pt. 245-7°C ;

^1H (δ , CDCl_3 , 400 MHz) 2.6 (3H, s), 6.6 (2H, s), 7.1-7.25 (3H, m), 7.3 (1H, d), 7.5 (1H, d), 7.7-7.8 (2H, m), 8.15 (1H, s), 8.25 (1H, d);

LRMS 308, 310 (MH);

20 El.Anal. Found: C, 70.16; H, 4.55; N, 13.54. Calcd for $\text{C}_{18}\text{H}_{14}\text{ClN}_3$: C, 70.24; H, 4.59; N, 13.65.

Preparation 58 : 1-Chloro-7-(phenoxymethyl)isoquinoline

25 The title compound was prepared from phenol, and the off-white solid was used without further purification.

M.Pt. <60°C;

LRMS 270, 272 (MH).

30 Preparation 59 : 5-Carboxy-1-chloroisoquinoline hydrochloride

A solution of 5-carbethoxy-1-chloroisoquinoline (German Patent DE 2816863) (1.75 g, 7.4 mmol) and NaOH (0.8 g, 20 mmol) in MeOH-H₂O (50 mL, 4:1) was stirred at 23°C for 5 h. The solvents were evaporated *in vacuo* and the residue partitioned between CH₂Cl₂ and aqueous NaOH (2 M). The aqueous phase was acidified with conc HCl and extracted with copious EtOAc (x4). The combined organics were washed with brine, dried over MgSO₄ and concentrated *in vacuo* to leave 5-carboxy-1-chloroisoquinoline hydrochloride (1.8 g, 7.4 mmol) as a white solid.

¹H (δ, DMSO-*d*₆, 300 MHz) 7.8 (1H, dd), 8.4 (1H, d), 8.5 (1H, d), 8.6 (1H, d), 8.7 (1H, d), 13.6. (1H, br s);
LRMS 208, 210 (MH).

Preparation 60 : 5-Carboxymethoxy-1-chloroisoquinoline hydrochloride

The title compound was prepared in a similar manner to Preparation 59, from 5-(ethoxycarbonylmethoxy)-1-chloroisoquinoline, giving a white solid.

M.Pt. >200°C;

¹H (δ, DMSO-*d*₆, 300 MHz) 4.9 (2H, s), 7.2 (1H, d), 7.7 (1H, dd), 7.8 (1H, d), 8.0 (1H, d), 8.3 (1H, d), 12.6 (1H, br s);

LRMS 238 (MH).

Preparation 61 : 5-Carboxamido-1-chloroisoquinoline

A solution of 5-carboxy-1-chloroisoquinoline hydrochloride (395 mg, 1.62 mmol) in SOCl₂ (5 mL) containing DMF (1 drop) was heated at reflux under N₂ for 2 h. The solvents were evaporated *in vacuo* and the residue azeotroped with PhMe to yield 1-chloro-5-isoquinoyl chloride hydrochloride (1.62 mmol) as an off-white solid. The acid chloride was used immediately without purification or characterisation.

A solution of 1-chloro-5-isoquinoyl chloride hydrochloride (1.62 mmol) in an NH_3 saturated CH_2Cl_2 (25 mL) was stirred at 23°C for 18 h. The solvents were evaporated *in vacuo*, the residue redissolved in CH_2Cl_2 and washed with water, and with brine. The organic phase was dried over MgSO_4 and concentrated *in vacuo* to leave the crude product which was purified by trituration with ether to give 5-carboxamido-1-chloroisoquinoline (92 mg, 0.45 mmol) as a white solid.

^1H (δ , $\text{DMSO}-d_6$, 400 MHz) 7.7 (1H, br s), 7.8 (1 H, dd), 8.0 (1H, d), 8.1 (1H, br s), 8.2 (1H, d), 8.3 (1H, d), 8.4 (1H, d);

LRMS 206, 209 (MH);

Elemental Analysis - Found: C, 57.61; H, 3.33; N, 13.30. Calculated for $\text{C}_{10}\text{H}_7\text{ClN}_2\text{O} + 0.04\text{CH}_2\text{Cl}_2$: C, 57.42; H, 3.40; N, 13.34.

The compounds of Preparations 62 and 63 were prepared in a similar manner:

Preparation 62: 5-(Carbamoylmethoxy)-1-chloroisoquinoline

The title compound was prepared from 5-carboxymethoxy-1-chloroisoquinoline hydrochloride, as a white powder.

M.Pt. $163-6^\circ\text{C}$;

^1H (δ , $\text{DMSO}-d_6$, 400 MHz) 4.6 (2H, s), 7.2 (1H, d), 7.45 (1H, br s), 7.65 (1H, br s), 7.7 (1H, dd), 7.8 (1H, d), 8.25-8.2 (2H, m);

LRMS 237, 239 (MH);

El. Anal. Found: C, 51.83; H, 4.13; N, 11.07. Calcd for $\text{C}_{11}\text{H}_9\text{ClN}_2\text{O}_2 + \text{H}_2\text{O}$: C, 51.88; H, 4.35; N, 11.00.

Preparation 63 : 7-N-Benzylcarbamoyl-1-chloroisoquinoline

The title compound was prepared from 7-carboxy-1-chloroisoquinoline hydrochloride and benzylamine, and gave a tan-coloured solid.

M.Pt. $144-5^\circ\text{C}$;

^1H (δ , CDCl_3 , 400 MHz) 4.7 (2H, d), 6.7 (1H, br s), 7.45-7.25 (5H, m), 7.6 (1H, d), 7.85 (1H, d), 8.15 (1H, d), 8.3 (1H, d), 8.65 (1H, s);
LRMS 297 (MH), 593 (M_2H).

5 Preparation 64 : 1-Chloro-5-sulphamoylisoquinoline

To an ice-cold solution of fuming sulphuric acid (20% SO_3 , 2 mL) was added 1-chloroisoquinoline (1.0 g, 6.1 mmol) portionwise with stirring. After stirring at room temperature for 3 hours, the reaction was heated at 80°C for 18 h, then cooled in an ice bath,
10 poured onto ice (70 g), washed with ether, and concentrated *in vacuo*. The residues were treated with isopropanol giving a white solid which was filtered and dried to give 1-chloro-5-isoquinolinesulphonic acid (1.16 g, 4.77 mmol).

^1H (δ , D_2O , 400MHz) 7.6 (1H, t), 8.10.84 (4H, m);
LRMS 244 (MH).

15

A suspension of 1-chloro-5-isoquinolinesulphonic acid (1.14 g, 4.68 mmol) in thionyl chloride (13 mL) and DMF (0.3 mL, 3.9 mmol) was heated to reflux for 3 h. Concentration *in vacuo* and azeotroping with toluene gave 1-chloro-5-chlorosulphonylisoquinoline as an off-white solid which was used immediately.

20


A solution of 1-chloro-5-chlorosulphonylisoquinoline (613 mg, 2.34 mmol) in methylene chloride saturated with ammonia gas (20 mL) was stirred at RT for 18 h, concentrated *in vacuo* to a white solid and purified by column chromatography upon silica gel (preabsorbed) using EtOAc - hexanes (1:1) as eluant to give 1-chloro-5-sulphamoylisoquinoline as a white
25 solid (206 mg, 0.85 mmol).

M.Pt. $216-8^\circ\text{C}$;


^1H (δ , $\text{DMSO}-d_6$, 400 MHz) 7.8 (1H, s), 7.9 (1H, t), 8.4 (1H, d), 8.45 (1H, s), 8.5 (1H, d);
LRMS 243, 245 (MH);

Found: C, 44.46; H, 3.01; N, 11.49. Calcd for $\text{C}_9\text{H}_7\text{ClN}_2\text{O}_2\text{S}$: C, 44.54; H, 2.91; N, 11.54.

30

Preparation 65: 1-Chloro-7-sulphamoylisoquinoline

- 5 *n*-Butyllithium (0.35 mL, 2.5 M in hexanes, 0.875 mmol) was added dropwise to a stirred solution of 7-bromo-1-chloroisoquinoline (200 mg, 0.825 mmol) in tetrahydrofuran-ether (THF-Et₂O) (2.0 mL, 1:1) under N₂ at -78 °C. After 5 min, the mixture was added to a solution of sulphuryl chloride (SO₂Cl₂) (0.14 mL, 1.74 mmol) in hexane (2.0 mL) at -25 °C under N₂ and the mixture was warmed to 23 °C and stirred for 3 h. Concentrated aqueous ammonia (3.0 mL, 0.880) was added and then all solvents were evaporated *in vacuo*. The residue was suspended in EtOAc, washed with aqueous HCl (2 M), brine, and then evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (50:50 to 30:70) as eluant to give the title compound (37 mg, 0.152 mmol) as a white solid.
- 10
- 15 m.p. 220-222 °C.
¹H (CD₃OD, 400 MHz) δ 7.9 (1H, d), 8.2 (1H, d), 8.3 (1H, d), 8.4 (1H, d), 8.9 (1H, s) ppm.
 LRMS 243, 245 (MH⁺).

Preparation 66: 1-Chloro-7-phenylsulphamoylisoquinoline

- 20 *n*-Butyllithium (0.88 mL, 2.5 M in hexanes, 2.2 mmol) was added dropwise to a stirred solution of 7-bromo-1-chloroisoquinoline (500 mg, 2.06 mmol) in THF-ether (10 mL, 1:1)


under N₂ at -78 °C. After 5 min, the mixture was added to a solution of SO₂Cl₂ (0.35 mL, 4.36 mmol) in hexane (10 mL) at -25 °C under N₂, the mixture was warmed to 23 °C and stirred for 4.5 h. The solvents were evaporated *in vacuo*, azeotroping with PhMe, the residue was suspended in CH₂Cl₂ (12 mL) and then aniline (0.25 mL, 2.74 mmol) and NEt₃ (1.15 mL, 8.25 mmol) were added. The mixture was stirred at room temperature overnight, washed with aqueous HCl (2 M), brine, and then evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (80:20 to 50:50) as eluant to give the title compound (116 mg, 0.36 mmol) as an off-white solid.

¹H (CD₃OD, 400 MHz) δ 7.0-7.15 (3H, m), 7.2-7.25 (2H, m), 7.8 (1H, d), 8.1 (2H, 2xd), 8.4 (1H, d), 8.7 (1H, s) ppm.

LRMS 319, 321 (MH⁺).

Preparation 67: 7-Chlorosulphonyl-1,4-dichloroisoquinoline

(i)




A solution of *N*-chlorosuccinimide (9.66 g, 72 mmol) in acetonitrile (MeCN) (80 mL) was added dropwise to a stirred solution of 1-(2*H*)-isoquinolone (10 g, 69 mmol) in MeCN (250 mL) which was being heated under reflux. The mixture was heated under reflux for an additional 1.5 h and then cooled to room temperature. The resulting precipitate was collected by filtration, with MeCN rinsing, and then dried *in vacuo* to give 4-chloro-1-(2*H*)-isoquinolone (11.3 g, 62.9 mmol) as a pale pink solid.

¹H (DMSO-*d*₆, 300 MHz) δ 7.5 (1H, s), 7.6 (1H, dd), 7.8-7.9 (2H, m), 8.25 (1H, d), 11.5 (1H, br s), ppm.

LRMS 180, 182 (MH⁺), 359, 361, 363 (M₂H⁺).

(ii)

74




4-Chloro-1-(2H)-isoquinolone (20.62 g, 115 mmol) was added portionwise to stirred chlorosulphonic acid (61 mL, 918 mmol) at 0 °C. The mixture was heated at 100 °C for 3.5 d and then cooled to room temperature. The reaction mixture was added in small portions onto ice-water [CAUTION] and the resulting precipitate was collected by filtration. The solid was washed with water, triturated with MeCN and then dried *in vacuo* to give 4-chloro-7-chlorosulphonyl-1-(2H)-isoquinolone (18.75 g, 67.4 mmol) as a cream solid.

¹H (DMSO-*d*₆, 400 MHz) δ 7.45 (1H, s), 7.8 (1H, d), 8.0 (1H, d), 8.5 (1H, s), 11.5 (1H, br s)

ppm.

Found: C, 39.37; H, 2.09; N, 4.94. Calc for C₉H₅Cl₂NO₃S: C, 38.87; H, 1.81; N, 5.04.

(iii)



Phosphorus oxychloride (POCl₃) (9.65 mL, 103.5 mmol) was added to a stirred suspension of 4-chloro-7-chlorosulphonyl-1-(2H)-isoquinolone (22.1 g, 79.6 mmol) in MeCN (500 mL) at room temperature and the mixture was then heated at reflux for 15 h. On cooling, the MeCN solution was decanted from the insoluble sludge and evaporated *in vacuo*. The residue was extracted with hot EtOAc and evaporated to leave a solid which was stirred with Et₂O (1.2 L) at room temperature overnight. The ethereal solution was decanted from the insoluble


material and evaporated *in vacuo* to give 7-chlorosulphonyl-1,4-dichloroisoquinoline (20 g, 67 mmol) as a pale yellow solid.

^1H (DMSO- d_6 , 400 MHz) δ 8.2 (2H, s), 8.5 (1H, s), 8.55 (1H, s) ppm.

Anal. Found: C, 37.19; H, 1.34; N, 4.77. Calc for $\text{C}_9\text{H}_4\text{Cl}_3\text{NO}_2\text{S}$: C, 36.45; H, 1.36; N, 4.72.

5

Preparation 68: 1,4-Dichloro-7-sulphamoylisoquinoline




- 10 7-chlorosulphonyl-1,4-dichloroisoquinoline (110 mg, 0.37 mmol) was dissolved in a solution of saturated methanolic ammonia (NH_3) (10 mL) and the solution stirred at room temperature for 1.5 hours. The solvents were evaporated *in vacuo* and the residue was azeotroped with CH_2Cl_2 and then partitioned between EtOAc and water. The organic phase was washed with brine, dried (MgSO_4) and evaporated *in vacuo* to give 1,4-dichloro-7-sulphamoylisoquinoline
- 15 (98 mg, 0.35 mmol) as a white solid.

^1H (DMSO- d_6 , 400 MHz) δ 7.8 (2H, s), 8.35 (1H, d), 8.45 (1H, d), 8.6 (1H, s), 8.75 (1H, s) ppm.

LRMS 276, 278 (MH^+).

- 20 Preparation 69: 7-Cyclopentylsulphamoyl-1,4-dichloroisoquinoline




A mixture of cyclopentylamine (0.10 mL, 1.0 mmol), NEt₃ (0.17 mL, 1.2 mmol) and 7-chlorosulphonyl-1,4-dichloroisoquinoline (250 mg, 0.84 mmol) in CH₂Cl₂ (15 mL) was stirred at 23 °C for 18 h. The mixture was diluted with CH₂Cl₂ (30 mL), washed with dilute HCl (2 M), saturated aqueous sodium bicarbonate (NaHCO₃), brine, dried (MgSO₄) and evaporated *in vacuo* to give the title compound (250 mg, 0.72 mmol) as a white solid..
mp 165-167 °C (dec).

¹H (CDCl₃, 300 MHz) δ 1.3-1.95 (8H, m), 3.75 (1H, sextet), 4.6 (1H, d), 8.2 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 346 (MH⁺).

Found: C, 48.76; H, 4.04; N, 7.98. Calc for C₁₄H₁₄Cl₂N₂O₂S: C, 48.71; H, 4.09; N, 8.11.

Preparation 70: 1,4-Dichloro-7-pyrrolidinosulphonylisoquinoline



The title compound was prepared by same the general method as Preparation 69.

mp 197-199 °C.


¹H (CDCl₃, 300 MHz) δ 1.8 (4H, m), 3.4 (4H, m), 8.2 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.8 (1H, s) ppm.

LRMS 331, 333 (MH⁺).

Found: C, 47.23; H, 3.60; N, 8.32. Calc for C₁₃H₁₂Cl₂N₂O₂S: C, 47.14; H, 3.65; N, 8.46.

Preparation 71: 1,4-Dichloro-7-morpholinosulphonylisoquinoline

77



The title compound was prepared by same the general method as Preparation 69.


mp 170-171 °C.

- 5 ^1H (CDCl_3 , 400 MHz) δ 3.1 (4H, s), 3.8 (4H, s), 8.1 (1H, d), 8.4 (1H, s), 8.5 (1H, d), 8.8 (1H, s) ppm.

LRMS 347, 349 (MH^+).

Found: C, 44.90; H, 3.43; N, 7.83. Calc for $\text{C}_{13}\text{H}_{12}\text{Cl}_2\text{N}_2\text{O}_3\text{S}$: C, 44.97; H, 3.48; N, 8.07.

10 Preparation 72: 1,4-Dichloro-7-(N-methylpiperazino)sulphonylisoquinoline hydrochloride



The title salt was prepared by same the general method, see Preparation 69.

- 15 mp 260.5-261.5 °C.

^1H (CDCl_3 , 400 MHz) δ 2.8 (3H, s), 3.1 (2H, br s), 3.5 (4H, br m), 4.0 (2H, br d), 8.1 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.8 (1H, s), 13.5 (1H, br s) ppm.


LRMS 360, 362 (MH^+).

Found: C, 41.93; H, 4.15; N, 10.08. Calc for $\text{C}_{14}\text{H}_{15}\text{Cl}_2\text{N}_3\text{O}_2\text{S} \cdot \text{HCl} \cdot 0.4\text{H}_2\text{O}$: C, 41.63; H,

- 20 4.19; N, 10.40.

Preparation 73: 7-Bromo-4-chloro-1(2H)-isoquinolone

78



A solution of *N*-chlorosuccinimide (4.13 g, 31 mmol) in MeCN (50 mL) was added dropwise to a stirred solution of 7-bromo-1-(2*H*)-isoquinolone (6.6 g, 29.5 mmol) in MeCN (150 mL) which was heating under reflux. The mixture was heated under reflux for an additional 3 h and then cooled to room temperature. The resulting precipitate was collected by filtration, with MeCN rinsing, and then dried *in vacuo* to give 7-bromo-4-chloro-1(2*H*)-isoquinolone (6.72 g, 26.0 mmol) as a white solid.


mp 241-243 °C.

¹H (DMSO-*d*₆, 300 MHz) δ 7.5 (1H, s), 7.73 (1H, d), 7.8 (1H, dd), 8.3 (1H, s) ppm.

LRMS 259 (MH⁺), 517 (M₂H⁺).

Anal. Found: C, 41.69; H, 1.90; N, 5.37. Calc for C₉H₅BrClNO: C, 41.80; H, 1.95; N, 5.42.

Preparation 74: 4-Chloro-7-(phenylsulfanyl)-1(2*H*)-isoquinolone



NaH (45 mg, 80% dispersion in mineral oil, 1.5 mmol) was added to a stirred solution of 7-bromo-4-chloro-1-(2*H*)-isoquinolone (390 mg, 1.5 mmol) in THF (15 mL) under N₂ at 0 °C and the mixture was stirred for 5-10 min which gave a clear orange solution. This solution was cooled to -78 °C, a solution of *n*-BuLi (0.60 mL, 2.5 M in hexanes, 1.5 mmol) was added dropwise and the solution was stirred for an additional 15 min. A solution of *S*-phenyl benzenethiosulphate (PhSO₂SPh) (378 mg, 1.5 mmol) in THF (5 mL) was added, the solution


was stirred at -70 °C for 10 min and then allowed to warm slowly to room temperature. Water (30 mL) was added and the mixture was extracted with EtOAc (3x20 mL). The combined organic extracts were washed with water, brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5) as eluant, followed by recrystallisation from EtOAc, to give 4-chloro-7-(phenylsulfanyl)-1-(2*H*)-isoquinolone (186 mg, 0.64 mmol) as a white solid. A second crop of material (40 mg, 0.14 mmol) was recovered from the mother liquors.

¹H (DMSO-*d*₆, 300 MHz) δ 7.35-7.5 (6H, m), 7.7 (1H, d), 7.8 (1H, d), 8.0 (1H, s) ppm.

LRMS 288, 290 (MH⁺), 575 (M₂H⁺).

Anal. Found: C, 61.85; H, 3.48; N, 4.81. Calc for C₁₅H₁₀ClNOS•0.25H₂O: C, 61.64; H, 3.62; N, 4.79.

Preparation 75: 1,4-Dichloro-7-(phenylsulfanyl)isoquinoline




POCl₃ (46 μL, 0.50 mmol) was added to a stirred suspension of 4-chloro-7-(phenylsulfanyl)-1-(2*H*)-isoquinolone (120 mg, 0.42 mmol) in MeCN (2 mL) at 23 °C, and the mixture was heated at reflux for 1.5 h which gave a clear solution. This cooled solution was poured into water (20 mL) and the mixture was extracted with EtOAc (x3). The combined organic extracts were washed with brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (90:10) as eluant to give 1,4-dichloro-7-(phenylsulfanyl)isoquinoline (92 mg, 0.30 mmol) as an oil which solidified on standing.

¹H (CDCl₃, 300 MHz) δ 7.45 (3H, m), 7.55 (2H, m), 7.65 (1H, dd), 8.1 (1H, d), 8.1 (1H, s), 8.3 (1H, s) ppm.

LRMS 306, 308 (MH^+).

Anal. Found: C, 57.90; H, 2.99; N, 4.67. Calc for $C_{15}H_9Cl_2NS \cdot 0.25H_2O$: C, 57.98; H, 3.08; N, 4.51.

5 Preparation 76: 1,4-Dichloro-7-(phenylsulfonyl)isoquinoline



mCPBA (270 mg, 50-55% by wt, 0.78 mmol) was added to a stirred solution of 1,4-dichloro-7-(phenylsulfanyl)isoquinoline (120 mg, 0.39 mmol) in CH_2Cl_2 (20 mL) at 23 °C and the mixture was stirred for 4 h. The solution was washed with aqueous $NaHCO_3$ (x3, 10%) brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (70:30) as eluant, followed by crystallisation with CH_2Cl_2 -*i*-Pr₂O, to give 1,4-dichloro-7-(phenylsulfonyl)isoquinoline (87 mg, 0.25 mmol) as a white solid.


1H ($CDCl_3$, 300 MHz) δ 7.5-7.7 (3H, m), 8.05 (2H, d), 8.15 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 9.05 (1H, s) ppm.

LRMS 338, 340 (MH^+).

Anal. Found: C, 52.55; H, 2.59; N, 4.10. Calc for $C_{15}H_9Cl_2NO_2S \cdot 0.25H_2O$: C, 52.56; H, 2.79; N, 4.09.

CLAIMS

1. A compound of formula (I) :-



or a pharmaceutically acceptable salt thereof, wherein

one of R^1 and R^2 is H and the other is $N=C(NH_2)_2$ or $NHC(=NH)NH_2$,

R^3 is H, halogen, C_{1-6} alkyl optionally substituted by one or more halogen, or C_{1-6} alkoxy optionally substituted by one or more halogen,

R^4 , R^5 , R^6 and R^7 are each independently H, OH, halogen, C_{1-6} alkyl optionally substituted by one or more substituents independently selected from halogen or OH, C_{1-6} alkoxy optionally substituted by one or more halogen, CN, $CO(C_{1-6}$ alkyl optionally substituted by one or more halogen), $(C_m - \text{alkylene})CO_2R^8$, $O(C_n - \text{alkylene})CO_2R^8$, $O(C_n - \text{alkylene})CN$, $(C_n - \text{alkylene})CN$, $(C_m - \text{alkylene})CONR^9R^{10}$, $(C_m - \text{alkylene})NR^9COR^{10}$, $O(C_n - \text{alkylene})CONR^9R^{10}$, $(C_m - \text{alkylene})NR^9SO_2R^{11}$, $(C_m - \text{alkylene})S(O)_pR^{11}$, $(C_m - \text{alkylene})SO_2NR^9R^{10}$, $CH=CHCOR^8$, $CH=CHCONR^9R^{10}$, $CH=CHSO_2R^8$, $CH=CHSO_2NR^9R^{10}$, $CH=CHSO_2\text{aryl}$, or

a group of formula X-aryl or X-het,

or, where two of R^4 , R^5 , R^6 and R^7 are attached to adjacent carbon atoms, they can be taken together to form an $-O(C_n - \text{alkylene})O-$ moiety,

R^8 is H, C_{1-6} alkyl optionally substituted by one or more halogen, or aryl(C_{1-6} alkylene),

R⁹ and R¹⁰ are each independently H, C₁₋₆ alkyl optionally substituted by one or more halogen, aryl(C₁₋₆ alkylene), aryl, heteroaryl or heteroaryl(C₁₋₆ alkylene), or R⁹ and R¹⁰ may be linked together by an alkylene moiety to form, with the atoms to which they are attached, a 4- to 7-membered ring optionally incorporating an additional hetero-
 5 group selected from an O or S atom or a NR¹² group,

R¹¹ is aryl, heteroaryl, or C₁₋₆ alkyl optionally substituted by one or more halogen,

10 R¹² is H, C₁₋₆ alkyl optionally substituted by one or more halogen, or CO(C₁₋₆ alkyl optionally substituted by one or more halogen),

X is a direct link, C_n - alkylene, O, (C_n - alkylene)O, O(C_n - alkylene), CH(OH), C(C₁₋₆ alkyl)OH, CO, S(O)_p(C_m - alkylene), (C_m - alkylene)S(O)_p, CH=CH, or C≡C,

15 "aryl" is phenyl or naphthyl optionally substituted by one or more substituents independently selected from halogen, C₁₋₆ alkyl optionally substituted by one or more substituents independently selected from halogen and OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, CO(C₁₋₆ alkyl optionally substituted by one or more halogen), (C_m - alkylene)CO₂R¹³, O(C_n - alkylene)CO₂R¹³, (C_m -
 20 alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴COR¹⁵, O(C_n - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)S(O)_pR¹³, (C_m - alkylene)SO₂NR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴SO₂R¹⁶, CH=CHSO₂R¹³, CH=CHSO₂NR¹⁴R¹⁵, CH=CHSO₂aryl¹, CH=CHCOR¹³, and CH=CHCONR¹⁴R¹⁵,

25 "heteroaryl" is an optionally benzo-fused 5- or 6-membered heterocyclic group linked by any available atom in the heterocyclic or benzo-ring (if present), which heterocyclic group is selected from dioxolyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl and pyranlyl,
 said "heteroaryl" group being optionally substituted by one or more substituents
 30 independently selected from halogen, C₁₋₆ alkyl optionally substituted by one or more

substituents independently selected from halogen or OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, CO(C₁₋₆ alkyl optionally substituted by one or more halogen), (C_m - alkylene)CO₂R¹³, O(C_n - alkylene)CO₂R¹³, (C_m - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴COR¹⁵, O(C_n - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴SO₂R¹⁶, (C_m - alkylene)S(O)_pR¹³, (C_m - alkylene)SO₂NR¹⁴R¹⁵, CH=CHCOR¹³, CH=CHCONR¹⁴R¹⁵, CH=CHSO₂R¹³, CH=CHSO₂NR¹⁴R¹⁵, or CH=CHSO₂aryl¹,

“het” is an optionally benzo-fused 5- or 6-membered heterocyclic group linked to the “X” moiety by any available atom in the heterocyclic or benzo-ring (if present), which heterocyclic group is selected from dioxolyl, dioxolanyl, furyl, thienyl, pyrrolyl, oxazolyl, oxazinyl, thiazinyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl and pyranlyl, or a fully unsaturated, partially or fully saturated analogue thereof, such “het” group being optionally substituted by one or more substituents independently selected from halogen, C₁₋₆ alkyl optionally substituted by one or more substituents independently selected from halogen and OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, CO(C₁₋₆ alkyl optionally substituted by one or more halogen), (C_m - alkylene)CO₂R¹³, O(C_n - alkylene)CO₂R¹³, (C_m - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴COR¹⁵, O(C_n - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴SO₂R¹⁶, (C_m - alkylene)S(O)_pR¹³, (C_m - alkylene)SO₂NR¹⁴R¹⁵, CH=CHCOR¹³, CH=CHCONR¹⁴R¹⁵, CH=CHSO₂R¹³, CH=CHSO₂NR¹⁴R¹⁵, and CH=CHSO₂aryl¹,

“aryl¹” is phenyl or naphthyl optionally substituted by one or more substituents independently selected from halogen, C₁₋₆ alkyl optionally substituted by one or more substituents independently selected from halogen or OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, CO(C₁₋₆ alkyl optionally substituted by one or more halogen), (C_m - alkylene)CO₂R¹³, O(C_n - alkylene)CO₂R¹³, (C_m - alkylene)CONR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴COR¹⁵, O(C_n - alkylene)CONR¹⁴R¹⁵, (C_m -

alkylene)S(O)_pR¹³, (C_m - alkylene)SO₂NR¹⁴R¹⁵, (C_m - alkylene)NR¹⁴SO₂R¹⁶, CH=CHSO₂R¹³, CH=CHSO₂NR¹⁴R¹⁵, CH=CHCOR¹³, and CH=CHCONR¹⁴R¹⁵,

R¹³ is H, C₁₋₆ alkyl optionally substituted by one or more halogen, or aryl²(C₁₋₆ alkylene),

5

R¹⁴ and R¹⁵ are each independently H, C₁₋₆ alkyl optionally substituted by one or more halogen, aryl²(C₁₋₆ alkylene), aryl², heteroaryl¹ or heteroaryl¹(C₁₋₆ alkylene), or R⁹ and R¹⁰ may be linked together by an alkylene moiety to form, with the atoms to which they are attached, a 4- to 7-membered ring optionally incorporating an additional hetero-

10

group selected from an O or S atom or a NR¹² group,

R¹⁶ is aryl², heteroaryl¹, or C₁₋₆ alkyl optionally substituted by one or more halogen,

“aryl²” is phenyl or naphthyl optionally substituted by one or more substituents independently selected from halogen, C₁₋₆ alkyl optionally substituted by one or more substituents independently selected from halogen or OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, or CO(C₁₋₆ alkyl optionally substituted by one or more halogen),

15

“heteroaryl¹” is an optionally benzo-fused 5- or 6-membered heterocyclic group linked by any available atom in the heterocyclic or benzo-ring (if present), which heterocyclic group is selected from dioxolyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl and pyranlyl,

20

said “heteroaryl¹” group being optionally substituted by one or more substituents independently selected from halogen, C₁₋₆ alkyl optionally substituted by one or more substituents independently selected from halogen or OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, or CO(C₁₋₆ alkyl optionally substituted by one or more halogen),

25

30

wherein the "C-alkylene" linking groups in the definitions above are linear or branched, and are optionally substituted by one or more (C₁₋₆ alkyl optionally substituted by one or more halogen) groups,

5 m is an integer from 0 to 3,

n is an integer from 1 to 3,

and

10

p is an integer from 0 to 2.

2. A compound or salt according to claim 1 wherein R¹ is N=C(NH₂)₂ or NHC(=NH)NH₂ and R² is H.

15

3. A compound or salt according to claim 1 or 2 wherein R³ is H, halogen or C₁₋₆ alkyl optionally substituted by one or more halogen.

20

4. A compound or salt according to any preceding claim wherein R⁴ is H, OH, halogen, C₁₋₆ alkyl optionally substituted by one or more substituents independently selected from halogen or OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, (C_m - alkylene)CONR⁹R¹⁰, O(C_n - alkylene)CONR⁹R¹⁰, (C_m - alkylene)SO₂NR⁹R¹⁰, or a group of formula X-aryl or X-het.

25

5. A compound or salt according to any preceding claim wherein R⁵ is H, halogen, or C₁₋₆ alkyl optionally substituted by one or more substituents independently selected from halogen or OH.

30

6. A compound or salt according to any preceding claim wherein R⁶ is H, halogen, C₁₋₆ alkyl optionally substituted by one or more substituents independently selected from halogen or

OH, C₁₋₆ alkoxy optionally substituted by one or more halogen, CN, O(C_n - alkylene)CN, (C_n - alkylene)CN, (C_m - alkylene)CONR⁹R¹⁰, (C_m - alkylene)CO₂R⁸, (C_m - alkylene)SO₂NR⁹R¹⁰, (C_m - alkylene)S(O)_p R¹¹ or a group of formula X-aryl or X-het.

- 5 7. A compound or salt according to any preceding claim wherein R⁷ is H.
8. A compound or salt according to any preceding claim wherein R³ is H, Cl, Br or methyl optionally substituted by one or more halogen.
- 10 9. A compound or salt according to any preceding claim wherein R⁴ is H, Br, OH, CN, C₁₋₆ alkoxy, C₁₋₆ alkyl optionally substituted by one or more OH, SO₂NR⁹R¹⁰, CONR⁹R¹⁰, OCH₂CONR⁹R¹⁰, OCH₂aryl, het or aryl.
10. A compound or salt according to any preceding claim wherein R⁵ is H, Br or methyl
- 15 optionally substituted by one or more halogen.
11. A compound or salt according to any preceding claim wherein R⁶ is H, Cl, Br, C₁₋₆ alkyl optionally substituted by one or more OH, C₁₋₆ alkoxy, CN, (C_m - alkylene)CONR⁹R¹⁰, (C_m - alkylene)CO₂R⁸, (C_m - alkylene)S(O)_pR¹¹, (C_m - alkylene)SO₂NR⁹R¹⁰ or a group of formula
- 20 X-aryl or X-het, where X is a direct link, CH=CH, CH(OH), CO, OCH₂, CH₂O or CH₂.
12. A compound or salt according to any preceding claim wherein R³ is H, Cl, Br or methyl.
13. A compound or salt according to any preceding claim wherein R⁴ is H, Br, OH, CN, C₁₋₆
- 25 alkoxy, C₁₋₆ alkyl optionally substituted by one or more OH, SO₂NR⁹R¹⁰, CONH(aryl(C₁₋₆ alkyl)), CONH₂, OCH₂CONR⁹R¹⁰, OCH₂aryl, phenyl or naphthyl.
14. A compound or salt according to any preceding claim wherein R⁵ is H, Br or methyl.

15. A compound or salt according to any preceding claim wherein R^6 is H, Br, methyl optionally substituted by OH, ethyl optionally substituted by OH, cyclopentyl optionally substituted by OH, cyclohexyl optionally substituted by OH, C_{1-6} alkoxy, CN, $O(C_n - \text{alkylene})CN$, $(C_n - \text{alkylene})CN$, SO_2R^{11} , SR^{11} , $CONR^9R^{10}$, CO_2R^8 , $SO_2NR^9R^{10}$, a group of
 5 formula X-(optionally substituted phenyl) or X-het¹,
 where X is a direct link, CH=CH, CH(OH), CO, OCH₂, CH₂O or CH₂,
 and where the phenyl moiety linked via X is optionally substituted by one or more halogen, C_{1-6} alkyl optionally substituted by one or more substituents independently selected from halogen and OH, C_{1-6} alkoxy optionally substituted by one or more halogen, or CO_2R^{13} ,
 10 where "het¹" is an optionally benzo-fused dioxolyl, furyl, thienyl, imidazolyl, or a partially or fully saturated analogue thereof,
 and such "het¹" group linked via X being optionally substituted by one or more C_{1-6} alkyl optionally substituted by one or more substituents independently selected from halogen and OH.

15

16. A compound or salt according to any preceding claim wherein R^4 is H, Br, CN, OCH₃, SO_2NH_2 , CH₂OH, CONH₂, OCH₂CONH₂, CONHBn, OBn, OH or Ph.

17. A compound or salt according to any preceding claim wherein R^6 is H, Br, CO₂H, (E)CH=CHPh, Ph, OCH₃, 1,3-benzo[d]dioxol-5-yl, CN, CH₂OH, CONHBn, 4-methoxyphenyl, 1-hydroxycyclohexyl, 1-hydroxycyclopentyl, CPh, CH(OH)CH₃, CH(OH)Ph, CCH₃(OH)Ph, OCH₂Ph, SO₂Ph, SPh, CH₂OPh, SO₂NH₂, SO₂NHPh, SO₂NH(cyclopentyl), SO₂(pyrrolidino), SO₂(morpholino), SO₂(N-methylpiperazino), (2-methylimidazol-1-yl)methyl, (2-methylbenzimidazol-1-yl)methyl, benzofuran-2-yl, thien-3-yl, thien-2-yl, 4-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3-carboxyphenyl, 3-cyanophenyl or 3-chlorophenyl.
 20
 25

18. A compound or salt according to any preceding claim wherein R^6 is CH(OH)Ph, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,6-dimethoxyphenyl, SO₂NH₂,

SO₂NHPh, SO₂NH(cyclopentyl), SO₂(pyrrolidino), SO₂(morpholino), SO₂Ph, SPh, SO₂(N-methylpiperazino) or 3-carboxyphenyl.

19. A compound or salt according to claim 1 wherein R¹ is N=C(NH₂)₂ or NH(C(=NH)NH₂),
 5 each of R², R⁴, R⁵ and R⁷ are H, R³ is Br or Cl, and R⁶ is 2-methoxyphenyl, 4-methoxyphenyl, CH(OH)Ph, SO₂Ph, SPh, 3-carboxyphenyl or 3-methoxyphenyl.

20. A compound or salt according to claim 1 wherein two of R⁴, R⁵, R⁶ and R⁷ are attached to adjacent carbon atoms, and are taken together to form a OCH₂O moiety,
 10

21. A compound or salt according to claim 1 substantially as described herein in the Examples.

22. A compound or salt according to claim 1 selected from:
 15 (4-chloro-7-(2-methoxyphenyl)isoquinolin-1-yl)guanidine;
 (4-chloro-7-(3-methoxyphenyl)isoquinolin-1-yl)guanidine;
 (4-chloro-7-(4-methoxyphenyl)isoquinolin-1-yl)guanidine;
 (4-chloro-7-(2,6-dimethoxyphenyl)isoquinolin-1-yl)guanidine;
 (4-bromo-7-(3-methoxyphenyl)isoquinolin-1-yl)guanidine;
 20 (4-bromo-7-(4-methoxyphenyl)isoquinolin-1-yl)guanidine;
 (4-chloro-7-(α -hydroxybenzyl)isoquinolin-1-yl)guanidine;
 (4-chloro-7-(3-carboxyphenyl)isoquinolin-1-yl)guanidine;
 1-guanidino-7-sulphamoylisoquinoline;
 1-guanidino-7-phenylsulphamoylisoquinoline;
 25 4-chloro-1-guanidino-7-sulphamoylisoquinoline;
 4-chloro-7-cyclopentylsulphamoyl-1-guanidinoisoquinoline;
 4-chloro-1-guanidino-7-(1-pyrrolidinylsulphonyl)isoquinoline hydrochloride;
 4-chloro-1-guanidino-7-morpholinylsulphonylisoquinoline hydrochloride;
 4-chloro-1-guanidino-7-[(N-methylpiperazino)sulphonyl]isoquinoline;
 30 4-chloro-1-guanidino-7-(phenylsulphanyl)isoquinoline;

4-chloro-1-guanidino-7-(phenylsulphonyl)isoquinoline;
and the salts thereof.

23. A pharmaceutical composition comprising a compound or salt according to any previous
5 claim, in admixture with a compatible adjuvant, diluent or carrier.

24. A compound or salt as defined in any one of claims 1 to 22, for use as a medicament.


25. The use of a compound or salt as defined in any one of claims 1 to 22, in the manufacture of
10 a medicament for the treatment of a condition or process mediated by uPA.

26. The use according to claim 25, wherein the condition or process is selected from chronic
dermal ulcer, angiogenesis (neo-vascularization), bone restructuring, embryo implantation in
the uterus, infiltration of immune cells into inflammatory sites, ovulation, spermatogenesis,
15 tissue remodelling during wound repair and organ differentiation, fibrosis, local invasion of
tumours into adjacent areas, metastatic spread of tumour cells from primary to secondary
sites, and tissue destruction in arthritis.

27. A method of treating a condition or process mediated by uPA, which comprises
20 administration of an effective amount of a compound or salt according to any one of claims 1 to
22, or composition thereof as defined in claim 23.

28. A method according to claim 27, where the condition or process is chronic dermal ulcer
angiogenesis (neo-vascularization), bone restructuring, embryo implantation in the uterus,
25 infiltration of immune cells into inflammatory sites, ovulation, spermatogenesis, tissue
remodelling during wound repair and organ differentiation, fibrosis, local invasion of tumours
into adjacent areas, metastatic spread of tumour cells from primary to secondary sites, and
tissue destruction in arthritis.


29. A process for preparing a compound or salt according to claim 1 comprising reaction of a 1- or 3-aminoisoquinoline derivative (II) as appropriate, wherein R^3 , R^4 , R^5 , R^6 and R^7 are as defined in claim 1:



(II)


with cyanamide (NH_2CN) or another reagent which acts as a " $\text{NHC}^+=\text{NH}$ " synthon.

30. A process for preparing a compound or salt according to claim 1 comprising reaction of a 1- or 3-aminoisoquinoline derivative (II), as appropriate, as defined in claim 29, with a reagent which acts as a protected amidine(2+) synthon (IV):



(IV)

where P and P_1 are N-protecting groups, *via* formation of a compound of formula (V) or salt thereof:




(V)

and deprotection thereof.

91

31. A process for preparation of a compound of formula (I) according to claim 1, or salt thereof, comprising reaction of a compound of formula (VI) :



(VI)

- 5 wherein R³, R⁴, R⁵, R⁶ and R⁷ are as defined in claim 1 and where Z is attached at the 1- or 3-position as appropriate and is a leaving group, by displacement of the leaving group by the free base of guanidine.

32. A compound of formula (V) as defined in claim 30.

INTERNATIONAL SEARCH REPORT

International Application No

PC./EP 98/06353

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D217/22 C07D405/04 C07D401/06 C07D409/04 C07D491/04
A61K31/47 //(C07D491/04, 317:00, 221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HEECHUNG YANG ET AL: "Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses" JOURNAL OF MEDICINAL CHEMISTRY., vol. 33, no. 11, 1990, pages 2956-2961, XP002059264 WASHINGTON US cited in the application see the whole document ---	1, 23-28
A	SCHNEUR RACHLIN: "Basic antiinflammatory compounds. N,N,N-trisubstituted guanidines" JOURNAL OF MEDICINAL CHEMISTRY., vol. 13, no. 1, 1980, pages 13-20, XP002059265 WASHINGTON US *page 15, compound 18* -----	1, 23-28

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

25 January 1999

Date of mailing of the international search report

03/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/06353

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 27,28
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 27,28
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)